10-Q

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 10-Q
(Mark One)
ý	QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
For the quarterly period ended June 30, 2010
OR
¨	TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
For the transition period from ________________ to ______________
Commission File Number:  001-14273
CORE LABORATORIES N.V.
(Exact name of registrant as specified in its charter)
The Netherlands		Not Applicable
(State of other jurisdiction of		(I.R.S. Employer Identification No.)
incorporation or organization)
Herengracht 424
1017 BZ Amsterdam
The Netherlands		Not Applicable
(Address of principal executive offices)		(Zip Code)
(31-20) 420-3191
(Registrant's telephone number, including area code)
None
(Former name, former address and former fiscal year, if changed since last report)

    Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.     Yes ý  No ¨

    Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files).    Yes ý  No ¨

    Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, or a smaller reporting company.  See the definitions of "large accelerated filer," "accelerated filer" and "smaller reporting company" in Rule 12b-2 of the Exchange Act.

Large accelerated filer ý	Accelerated filer  ¨	Non-accelerated filer  ¨	Smaller reporting company  ¨
		(Do not check if a smaller reporting company)

    Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes ¨  No ý

    The number of common shares of the registrant, par value EUR 0.02 per share, outstanding at July 22, 2010 was 44,675,908.

CORE LABORATORIES N.V.
FORM 10-Q FOR THE QUARTER ENDED JUNE 30, 2010
INDEX
		Page
PART I - FINANCIAL INFORMATION
Item 1.	Financial Statements
	Consolidated Balance Sheets (Unaudited) at June 30, 2010 and December 31, 2009	1
	Consolidated Statements of Operations (Unaudited) for the Three Months Ended June 30, 2010 and 2009	2
	Consolidated Statements of Operations (Unaudited) for the Six Months Ended June 30, 2010 and 2009	3
	Consolidated Statements of Cash Flows (Unaudited) for the Six Months Ended June 30, 2010 and 2009	4
	Notes to the Unaudited Consolidated Interim Financial Statements	5
Item 2.	Management's Discussion and Analysis of Financial Condition and Results of Operations	17
Item 3.	Quantitative and Qualitative Disclosures About Market Risk	25
Item 4.	Controls and Procedures	25
PART II - OTHER INFORMATION
Item 1.	Legal Proceedings	26
Item 2.	Unregistered Sales of Equity Securities and Use of Proceeds	26
Item 6.	Exhibits	27
	Signature	28

PART I - FINANCIAL INFORMATION

Item 1. Financial Statements

CORE LABORATORIES N.V.

CONSOLIDATED BALANCE SHEETS

(In thousands, except share and per share data)

	June 30,			December 31,
	2010			2009
ASSETS	(Unaudited)
CURRENT ASSETS:
Cash and cash equivalents	$	173,622		$	181,045
Accounts receivable, net of allowance for doubtful accounts of $3,571 and   $3,202 at 2010 and 2009, respectively		137,565			133,758
Inventories, net		33,762			32,184
Prepaid expenses and other current assets		29,022			43,550
TOTAL CURRENT ASSETS		373,971			390,537
PROPERTY, PLANT AND EQUIPMENT, net		100,680			98,784
INTANGIBLES, net		9,191			6,520
GOODWILL		154,217			148,600
OTHER ASSETS		14,602			13,725
TOTAL ASSETS	$	652,661		$	658,166
LIABILITIES AND EQUITY
CURRENT LIABILITIES:
Accounts payable	$	39,528		$	33,009
Accrued payroll and related costs		23,140			24,368
Taxes other than payroll and income		6,817			8,183
Unearned revenues		18,472			16,528
Income tax payable		23,001			15,433
Short-term debt – Senior Exchangeable Notes		216,787			-
Other accrued expenses		9,667			8,887
TOTAL CURRENT LIABILITIES		337,412			106,408
LONG-TERM DEBT – SENIOR EXCHANGEABLE NOTES		-			209,112
DEFERRED COMPENSATION		18,143			16,866
DEFERRED TAX LIABILITIES		8,239			7,692
OTHER LONG-TERM LIABILITIES		32,603			36,330
COMMITMENTS AND CONTINGENCIES		-			-
EQUITY COMPONENT OF SHORT-TERM DEBT – SENIOR EXCHANGEABLE NOTES		21,871			-
EQUITY:
Preference shares, EUR 0.02 par value; 6,000,000 shares authorized, none issued or outstanding		-			-
Common shares, EUR 0.02 par value; 200,000,000 shares authorized, 51,039,912 issued and 44,675,908 outstanding at 2010 and 51,039,912 issued and 45,973,408 outstanding at 2009		1,430			1,430
Additional paid-in capital		37,149			61,719
Retained earnings		530,500			469,454
Accumulated other comprehensive (loss)		(6,365	)		(6,536	)
Treasury shares (at cost), 6,364,004 at 2010 and 5,066,504 at 2009		(330,757	)		(246,699	)
Total Core Laboratories N.V. shareholders' equity		231,957			279,368
Non-controlling interest		2,436			2,390
TOTAL EQUITY		234,393			281,758
TOTAL LIABILITIES AND EQUITY	$	652,661		$	658,166

The accompanying notes are an integral part of these consolidated financial statements.

1

CORE LABORATORIES N.V.

CONSOLIDATED STATEMENTS OF OPERATIONS

(In thousands, except per share data)

	Three Months Ended June 30,
	2010		2009
	(Unaudited)
REVENUES:
Services	$	153,010	$	134,671
Product sales		45,892		32,591
		198,902		167,262
OPERATING EXPENSES:
Cost of services, exclusive of depreciation expense shown below		96,411		84,401
Cost of product sales, exclusive of depreciation expense shown below		32,506		24,596
General and administrative expenses		9,211		6,684
Depreciation		5,430		5,724
Amortization		336		182
Other expense (income), net		1,288		(6,013	)
OPERATING INCOME		53,720		51,688
Interest expense		4,114		3,840
Income before income tax expense		49,606		47,848
Income tax expense		15,244		17,884
Net income		34,362		29,964
Net income attributable to non-controlling interest		146		157
Net income attributable to Core Laboratories N.V.	$	34,216	$	29,807
EARNINGS PER SHARE INFORMATION:
Basic earnings per share attributable to Core Laboratories N.V.	$	0.77	$	0.65
Diluted earnings per share attributable to Core Laboratories N.V.	$	0.71	$	0.64
Cash dividends per share	$	0.06	$	0.05
WEIGHTED AVERAGE COMMON SHARES OUTSTANDING:
Basic		44,651		45,911
Diluted		47,957		46,357

The accompanying notes are an integral part of these consolidated financial statements.

2

CORE LABORATORIES N.V.

CONSOLIDATED STATEMENTS OF OPERATIONS

(In thousands, except per share data)

	Six Months Ended June 30,
	2010		2009
	(Unaudited)
REVENUES:
Services	$	296,452	$	276,363
Product sales		90,787		69,775
		387,239		346,138
OPERATING EXPENSES:
Cost of services, exclusive of depreciation expense shown below		191,768		172,697
Cost of product sales, exclusive of depreciation expense shown below		62,737		52,332
General and administrative expenses		15,591		15,958
Depreciation		10,849		11,251
Amortization		671		363
Other expense (income), net		490		(4,770	)
OPERATING INCOME		105,133		98,307
Interest expense		8,173		7,640
Income before income tax expense		96,960		90,667
Income tax expense		30,312		31,464
Net income		66,648		59,203
Net income attributable to non-controlling interest		227		204
Net income attributable to Core Laboratories N.V.	$	66,421	$	58,999
EARNINGS PER SHARE INFORMATION:
Basic earnings per share attributable to Core Laboratories N.V.	$	1.48	$	1.28
Diluted earnings per share attributable to Core Laboratories N.V.	$	1.40	$	1.27
Cash dividends per share	$	0.12	$	0.10
WEIGHTED AVERAGE COMMON SHARES OUTSTANDING:
Basic		44,743		45,925
Diluted		47,396		46,383

The accompanying notes are an integral part of these consolidated financial statements.

3

CORE LABORATORIES N.V.

CONSOLIDATED STATEMENTS OF CASH FLOWS

(In thousands)

	Six Months Ended June 30,
	2010			2009
	(Unaudited)
CASH FLOWS FROM OPERATING ACTIVITIES:
Net income	$	66,648		$	59,203
Adjustments to reconcile net income to net cash provided by operating activities:
Net provision for (recoveries of) doubtful accounts		811			319
Provisions for inventory obsolescence		298			103
Equity in earnings of affiliates		(239	)		(78	)
Stock-based compensation		3,836			2,624
Depreciation and amortization		11,520			11,614
Non-cash interest expense		7,735			7,213
Gain on sale of assets		8			(345	)
Realization of pension obligation		171			117
(Increase) decrease in value of life insurance policies		765			(421	)
Deferred income taxes		(8,822	)		(8,145	)
Changes in assets and liabilities:
Accounts receivable		(4,618	)		20,028
Inventories		(1,876	)		(2,123	)
Prepaid expenses and other current assets		23,896			724
Other assets		(540	)		(252	)
Accounts payable		6,519			(14,748	)
Accrued expenses		7,698			1,948
Other long-term liabilities		(2,450	)		8,486
Net cash provided by operating activities		111,360			86,267
CASH FLOWS FROM INVESTING ACTIVITIES:
Capital expenditures		(12,696	)		(5,320	)
Patents and other intangibles		(142	)		(151	)
Acquisitions		(9,000	)		-
Proceeds from sale of assets		125			459
Premiums on life insurance		(921	)		(844	)
Net cash used in investing activities		(22,634	)		(5,856	)
CASH FLOWS FROM FINANCING ACTIVITIES:
Stock options exercised		295			302
Excess tax benefits from stock-based compensation		798			127
Non-controlling interest - dividends		(181	)		(246	)
Dividends paid		(5,375	)		(4,597	)
Repurchase of common shares		(91,686	)		(8,889	)
Net cash used in financing activities		(96,149	)		(13,303	)
NET CHANGE IN CASH AND CASH EQUIVALENTS		(7,423	)		67,108
CASH AND CASH EQUIVALENTS, beginning of period		181,045			36,138
CASH AND CASH EQUIVALENTS, end of period	$	173,622		$	103,246
Non-cash investing and financing activities:
Financed capital expenditures	$	-		$	2,871

The accompanying notes are an integral part of these consolidated financial statements.

4

CORE LABORATORIES N.V.

NOTES TO THE UNAUDITED CONSOLIDATED INTERIM FINANCIAL STATEMENTS

1.  BASIS OF PRESENTATION

The accompanying unaudited consolidated financial statements include the accounts of Core Laboratories N.V. and its subsidiaries for which we have a controlling voting interest and/or a controlling financial interest. These financial statements have been prepared in accordance with United States ("U.S.") generally accepted accounting principles ("GAAP") for interim financial information using the instructions to Form 10-Q and Article 10 of Regulation S-X. Accordingly, these financial statements do not include all of the information and footnote disclosures required by U.S. GAAP and should be read in conjunction with the financial statements and the summary of significant accounting policies and notes thereto included in our Annual Report on Form 10-K for the year ended December 31, 2009.

Core Laboratories N.V. uses the equity method of accounting for investments in which it has less than a majority interest and over which it does not exercise control. Non-controlling interest has been recorded to reflect outside ownership attributable to consolidated subsidiaries that are less than 100% owned.  In the opinion of management, all adjustments considered necessary for the periods presented have been included in these financial statements.  Furthermore, the operating results presented for the three and six months ended June 30, 2010 may not necessarily be indicative of the results that may be expected for the year ended December 31, 2010.

Core Laboratories N.V.'s balance sheet information for the year ended December 31, 2009 was derived from the 2009 audited consolidated financial statements but does not include all disclosures in accordance with U.S. GAAP.

At our annual meeting on June 10, 2010, the shareholders approved an amendment to increase the authorized shares of our common stock from 100 million to 200 million and to increase the authorized shares of our preference stock from 3 million to 6 million.  In addition, shareholders approved the two-for-one stock split authorized by the Supervisory Board and thereby reduced the par value of each share from EUR 0.04 to EUR 0.02. As a result of the stock split, shareholders of record on June 30, 2010 received an additional share of common stock for each common share held.  The additional shares were distributed on July 8, 2010.  All references in the consolidated financial statements and the accompanying notes to common shares, share prices, per share amounts and stock plans have been restated retroactively f or the stock split.

Certain reclassifications were made to prior period amounts in order to conform to the current period presentation.  These reclassifications had no impact on the reported net income for the three month and six month periods ended June 30, 2010.

References to "Core Lab", "we", "our" and similar phrases are used throughout this Quarterly Report on Form 10-Q and relate collectively to Core Laboratories N.V. and its consolidated subsidiaries.

2.  INVENTORIES

Inventories consist of the following (in thousands):

	June 30,		December 31,
	2010		2009
	(Unaudited)
Finished goods	$	22,503	$	22,161
Parts and materials		8,823		8,756
Work in progress		2,436		1,267
Total inventories, net	$	33,762	$	32,184

We include freight costs incurred for shipping inventory to customers in the Cost of Sales line of the Consolidated Statements of Operations.

3. GOODWILL AND INTANGIBLES

We account for intangible assets with indefinite lives, including goodwill, in accordance with the applicable accounting guidance, which requires us to evaluate these assets for impairment annually, or more frequently if an indication of impairment has occurred.  Based upon our most recent evaluation, we did not identify a triggering event; therefore, we have determined that goodwill is not impaired.  We amortize intangible assets with a defined term on a straight-line basis over their respective useful lives.

5

In January 2010, we acquired fracture diagnostics assets for $9.0 million in cash.  The acquisition was recorded in the Production Enhancement business segment and resulted in an increase of $5.6 million in goodwill and an increase of $3.2 million in intangible assets.  The intangible assets will be amortized over a period of 36 to 60 months.  The acquisition did not have a material impact to the Production Enhancement business segment or consolidated operating results for the six months ended June 30, 2010.  The remaining composition of goodwill by business segment at June 30, 2010 was consistent with the amounts disclosed in our Annual Report on Form 10-K as of December 31, 2009.

4.  DEBT AND CAPITAL LEASE OBLIGATIONS

Debt is summarized in the following table (in thousands):

	June 30,			December 31,
	2010			2009
	(Unaudited)
Senior exchangeable notes	$	238,658		$	238,658
Discount on senior exchangeable notes		(21,871	)		(29,546	)
Net senior exchangeable notes	$	216,787		$	209,112

In 2006, Core Laboratories LP, a wholly owned subsidiary of Core Laboratories N.V., issued $300 million aggregate principal amount of Senior Exchangeable Notes (the "Notes") which are fully and unconditionally guaranteed by Core Laboratories N.V. and mature on October 31, 2011.  The Notes bear interest at a rate of 0.25% per year paid on a semi-annual basis.

With the additional amortization of the discount on the Notes, the effective interest rate is 7.48% for the six-month period ended June 30, 2010, which resulted in additional non-cash interest expense of $3.9 million and $3.6 million for the three months ended June 30, 2010 and 2009, respectively, and $7.7 million and $7.1 million for the six months ended June 30, 2010 and 2009, respectively.  Each Note carries a $1,000 principal amount and is exchangeable into shares of Core Laboratories N.V. under certain circumstances at an exchange price of $46.21 per share, or 21.6434 shares per Note.  Upon exchange, holders will receive cash for the principal amount plus any amount related to fractional shares, and any excess exchange value will be delivered in whole shares of Core Laboratories N.V. common shares.  The carrying value of the equity component of the Notes is $84.4 million at June 30, 2010 and December 31, 2009. At June 30, 2010, the Notes were trading at 162.0% of their face value which would result in $148.0 million of value in excess of the principal. At December 31, 2009, the Notes were trading at 134% of their face value which would result in $81.1 million of value in excess of the principal.  There were 238,658 Notes outstanding at June 30, 2010.

Under the terms of the Notes, in the second quarter of 2010, the early exchange option for the holders of the Notes was enabled. As a result, the Notes can be exchanged during the third quarter of 2010 and will remain classified as a short-term liability at June 30, 2010.  In addition, the equity component of the Notes was classified as temporary equity to reflect the amount that could result in cash settlement at June 30, 2010.  In the first quarter of 2010, the early exchange option was enabled allowing the holders of the Notes to exchange them during the second quarter of 2010.  We received six requests during the second quarter of 2010 to exchange 28 Notes, which we will settle during the third quarter.

We maintain a revolving credit facility (the "Credit Facility") that allows for an aggregate borrowing capacity of $100.0 million. The Credit Facility provides an option to increase the commitment under the Credit Facility to $150.0 million, if certain conditions are met.  The Credit Facility bears interest at variable rates from LIBOR plus 0.5% to a maximum of LIBOR plus 1.125%.  Any outstanding balance under the Credit Facility is due in December 2010 when the Credit Facility matures.  Interest payment terms are variable depending upon the specific type of borrowing under this facility. Our available borrowing capacity under the Credit Facility was reduced by outstanding letters of credit and performance guarantees and bonds arranged totaling $12.6 million at June 30, 2010 relating to certain projects in pr ogress.  Our available borrowing capacity under the Credit Facility at June 30, 2010 was $87.4 million. As of June 30, 2010, we had $14.9 million of outstanding letters of credit and performance guarantees and bonds in addition to those under the Credit Facility.

5.  PENSIONS AND OTHER POSTRETIREMENT BENEFITS

We provide a noncontributory defined benefit pension plan covering substantially all of our Dutch employees (the "Dutch Plan") who were hired prior to 2007 based on years of service and final pay or career average pay, depending on when the employee began participating. Employees are immediately vested in the benefits earned.  We fund the future obligations of the Dutch Plan by purchasing investment contracts from a large multi-national insurance company.  The investment contracts are

6

purchased annually and expire after five years at which time they are replaced with new contracts that are adjusted to include changes in the benefit obligation for the current year and redemption of the expired contracts.  We determine the fair value of

these plan assets with the assistance of an actuary using observable inputs (Level 2).  We make annual premium payments to the insurance company, based on each employee's age and current salary.

The following table summarizes the components of net periodic pension cost under this plan for the three and six months ended June 30, 2010 and 2009 (in thousands):

	Three Months Ended June 30,						Six Months Ended June 30,
	2010			2009			2010			2009
	(Unaudited)						(Unaudited)
Service cost	$	304		$	265		$	627		$	518
Interest cost		352			339			728			663
Expected return on plan assets		(111	)		(186	)		(230	)		(364	)
Amortization of transition asset		(22	)		(22	)		(44	)		(44	)
Amortization of prior service cost		40			40			80			80
Amortization of net loss		95			61			189			122
Net periodic pension cost	$	658		$	497		$	1,350		$	975

During the six months ended June 30, 2010, we contributed approximately $1.1 million, as determined by the insurance company, to fund the estimated 2010 premiums on investment contracts held by the plan.

We have adopted a non-qualified deferred compensation plan that allows certain highly compensated employees to defer a portion of their salary, commission and bonus, as well as the amount of any reductions in their deferrals under the deferred compensation plan for employees in the United States (the "Deferred Compensation Plan"), due to certain limitations imposed by the U.S. Internal Revenue Code of 1986, as amended (the "Internal Revenue Code").  The Deferred Compensation Plan also provides for employer contributions to be made on behalf of participants equal in amount to certain forfeitures of, and/or reductions in, employer contributions that participants could have received under the 401(k) Plan in the absence of certain limitations imposed by the Internal Revenue Code. Employer contributions to the Deferred Compensation Plan vest ratably over a period of five years. Contributions to the plan are invested in equity and other investment fund assets, and carried on the balance sheet at fair value.  The benefits under these contracts are fully vested and payment of benefits generally commences as of the last day of the month following the termination of services except that the payment of benefits for select executives generally commences on the first working day following a six month waiting period following the date of termination.

On a recurring basis, we use the market approach to value certain assets and liabilities at fair value at quoted prices in an active market (Level 1) and certain assets and liabilities using significant other observable inputs (Level 2). We do not have any assets or liabilities measured at fair value on a recurring basis using significant unobservable inputs (Level 3). Gains and losses related to the fair value changes in the deferred compensation assets and liabilities are recorded in General and Administrative Expenses in the Consolidated Statements of Operations.  The following table summarizes the fair value balances (in thousands):

(Unaudited)			Fair Value Measurement at June 30, 2010
	Total		Level 1		Level 2		Level 3
Assets:
Deferred compensation plan trust assets	$	6,266	$	-	$	6,266	$	-
Liabilities:
Deferred compensation plan	$	9,894	$	1,767	$	8,127	$	-

			Fair Value Measurement at December 31, 2009
	Total		Level 1		Level 2		Level 3
Assets:
Deferred compensation plan trust assets	$	6,193	$	-	$	6,193	$	-
Liabilities:
Deferred compensation plan	$	9,366	$	1,339	$	8,027	$	-

7

6. COMMITMENTS AND CONTINGENCIES

From time to time, we may be subject to legal proceedings and claims that arise in the ordinary course of business.  We believe that the resolution of all litigation currently pending or threatened against us or any of our subsidiaries should not have a material adverse effect on our consolidated financial condition, results of operations or liquidity; however, because of the inherent uncertainty of litigation, we cannot provide assurance that the resolution of any particular claim or proceeding to which we or any of our subsidiaries is a party will not have a material adverse effect on our consolidated results of operations or liquidity for the period in which that resolution occurs.

7.  EQUITY

During the three months ended June 30, 2010, we repurchased 75,476 of our common shares for $5.2 million. Included in this total were rights to 35,476 shares valued at $2.5 million that were surrendered to us pursuant to the terms of a stock-based compensation plan, in consideration of the participants' tax burdens that may result from the issuance of common shares under this plan.  During the six months ended June 30, 2010, we repurchased 1,483,280 of our common shares for $91.7 million. Included in this total were rights to 42,534 shares valued at $2.9 million that were surrendered to us pursuant to the terms of a stock-based compensation plan, in consideration of the participants' tax burdens that may result from the issuance of common shares under this plan. Such common shares, unless cancelled, may be reissued for a variety of purposes such as future acquisitions, employee stock awards, possible exchange of the Notes or settlement of warrants.

During the three and six months ended June 30, 2010, we recognized tax benefits of $0.9 million and $0.8 million, respectively, relating to tax deductions in excess of book expense for stock-based compensation awards.  These tax benefits are recorded to additional paid-in capital to the extent deductions reduce current taxable income.

At the annual meeting of shareholders on June 10, 2010, the shareholders approved the cancellation of 1.3 million shares of our common stock currently held as treasury stock.  These treasury shares will be cancelled on or about August 14, 2010, after the expiration of the waiting period required under Dutch law.

In February and May 2010, we paid a quarterly dividend of $0.06 per share of common stock.  In addition, on July 12, 2010, we declared a quarterly dividend of $0.06 per share of common stock and a special non-recurring cash dividend of $0.65 per share of common stock for shareholders of record on July 23, 2010 and payable on August 23, 2010.

The following table summarizes our changes in equity for the six months ended June 30, 2010 (in thousands):

									Accumulated
			Additional						Other						Non-
	Common		Paid-In			Retained			Comprehensive			Treasury			Controlling			Total
(Unaudited)	Shares		Capital			Earnings			Income (Loss)			Stock			Interest			Equity
December 31, 2009	$	1,430	$	61,719		$	469,454		$	(6,536	)	$	(246,699	)	$	2,390		$	281,758
Stock options exercised		-		(1,353	)		-			-			1,648			-			295
Stock based-awards		-		(2,144	)		-			-			5,980			-			3,836
Tax benefit of stock-based awards issued		-		798			-			-			-			-			798
Repurchase of common shares		-		-			-			-			(91,686	)		-			(91,686	)
Dividends paid		-		-			(5,375	)		-			-			-			(5,375	)
Equity component of short-term debt		-		(21,871	)		-			-			-			-			(21,871	)
Non-controlling interest dividend		-		-			-			-			-			(181	)		(181	)
Comprehensive income:
Amortization of pension, net of tax		-		-			-			171			-			-			171
Net income		-		-			66,421			-			-			227			66,648
Total comprehensive income																			66,819
June 30, 2010	$	1,430	$	37,149		$	530,500		$	(6,365	)	$	(330,757	)	$	2,436		$	234,393

Comprehensive Income

8

The components of comprehensive income consisted of the following (in thousands):

	Three months ended June 30,				Six months ended June 30,
	2010		2009		2010		2009
	(Unaudited)				(Unaudited)
Net income	$	34,362	$	29,964	$	66,648	$	59,203
Realization of pension obligation		86		59		171		117
Total comprehensive income	$	34,448	$	30,023	$	66,819	$	59,320

Accumulated other comprehensive income (loss) consisted of the following (in thousands):

	June 30,			December 31,
	2010			2009
	(Unaudited)
Prior service cost	$	(911	)	$	(971	)
Transition asset		356			389
Unrecognized net actuarial loss		(5,810	)		(5,954	)
Total accumulated other comprehensive loss	$	(6,365	)	$	(6,536	)

8.  EARNINGS PER SHARE

We compute basic earnings per common share by dividing net income available to common shareholders by the weighted average number of common shares outstanding during the period. Diluted earnings per common and potential common shares include additional shares in the weighted average share calculations associated with the incremental effect of dilutive employee stock options, restricted stock awards and contingently issuable shares, as determined using the treasury stock method. The following table summarizes the calculation of weighted average common shares outstanding used in the computation of diluted earnings per share (in thousands):

	Three Months Ended June 30,				Six Months Ended June 30,
	2010		2009		2010		2009
	(Unaudited)				(Unaudited)
Weighted average basic common shares outstanding		44,651		45,911		44,743		45,925
Effect of dilutive securities:
Stock options		55		96		56		142
Contingent shares		44		32		37		30
Restricted stock and other		568		318		550		286
Senior exchangeable notes		1,823		-		1,586		-
Warrants		816		-		424		-
Weighted average diluted common and potential common shares outstanding		47,957		46,357		47,396		46,383

In 2006, we sold warrants on our common shares, which currently have an exercise price of $62.21 per share, and will settle in January 2012.  The net value of these warrants will be settled with Core Laboratories N.V. common shares.  Included in the table above are 816,000 and 424,000 shares which were added to the share count for the three and six months ended June 30, 2010 because the average share price exceeded the strike price of the warrants.  These shares were included in calculating the impact to our dilutive earnings per share for the three and six months ended June 30, 2010.

9

9. OTHER EXPENSE (INCOME), NET

The components of other expense (income), net, were as follows (in thousands):

	Three Months Ended June 30,						Six Months Ended June 30,
	2010			2009			2010			2009
	(Unaudited)						(Unaudited)
Gain on sale of assets	$	39		$	(268	)	$	8		$	(345	)
Foreign exchange loss (gain)		1,712			(2,897	)		1,621			(1,009	)
Interest income		(130	)		(59	)		(142	)		(98	)
Non-income tax accrual		-			(2,500	)		-			(2,500	)
Rents and royalties		(218	)		(508	)		(700	)		(849	)
Other, net		(115	)		219			(297	)		31
Total other expense (income), net	$	1,288		$	(6,013	)	$	490		$	(4,770	)

As a result of finalizing a non-income related tax settlement agreement, we released the remaining $2.5 million of the contingent liability during the second quarter of 2009.

Foreign exchange losses (gains) by currency are summarized in the following table (in thousands):

	Three Months Ended June 30,						Six Months Ended June 30,
	2010			2009			2010			2009
	(Unaudited)						(Unaudited)
Australian Dollar	$	103		$	(300	)	$	103		$	(278	)
British Pound		158			(304	)		416			(232	)
Canadian Dollar		149			(1,115	)		(236	)		(767	)
Euro		1,619			(376	)		1,589			(213	)
Russian Ruble		(69	)		(372	)		(15	)		224
Venezuelan Bolivar		(202	)		(1	)		(191	)		(1	)
Other currencies, net		(46	)		(429	)		(45	)		258
Total loss (gain)	$	1,712		$	(2,897	)	$	1,621		$	(1,009	)

10.  INCOME TAX EXPENSE

The effective tax rates for the three months ended June 30, 2010 and 2009 were 30.7% and 37.4%, respectively.  The effective tax rates for year to date 2010 and 2009 were 31.3% and 34.7%, respectively. The higher effective tax rate for 2009 was primarily due to a write down of assets in Venezuela without a tax benefit in the second quarter last year.

11.  SEGMENT REPORTING

We operate our business in three reportable segments:  (1) Reservoir Description, (2) Production Enhancement and (3) Reservoir Management.  These business segments provide different services and utilize different technologies.

*	Reservoir Description: Encompasses the characterization of petroleum reservoir rock, fluid and gas samples. We provide analytical and field services to characterize properties of crude oil and petroleum products to the oil and gas industry.
*	Production Enhancement: Includes products and services relating to reservoir well completions, perforations, stimulations and production. We provide integrated services to evaluate the effectiveness of well completions and to develop solutions aimed at increasing the effectiveness of enhanced oil recovery projects.
*	Reservoir Management: Combines and integrates information from reservoir description and production enhancement services to increase production and improve recovery of oil and gas from our clients' reservoirs.

10

Results for these business segments are presented below.  We use the same accounting policies to prepare our business segment results as are used to prepare our Consolidated Financial Statements.  We evaluate performance based on income or loss before income tax, interest and other non-operating income (expense). Summarized financial information concerning our segments is shown in the following table (in thousands):

(Unaudited)	Reservoir Description		Production Enhancement		Reservoir Management		Corporate & Other 1			Consolidated
Three Months Ended June 30, 2010
Revenues from unaffiliated customers	$	106,528	$	79,717	$	12,657	$	-		$	198,902
Inter-segment revenues		248		419		427		(1,094	)		-
Segment operating income		25,074		26,152		3,672		(1,178	)		53,720
Total assets		258,759		190,512		14,245		189,145			652,661
Capital expenditures		4,600		720		219		1,002			6,541
Depreciation and amortization		3,523		1,626		166		451			5,766
Three Months Ended June 30, 2009
Revenues from unaffiliated customers	$	103,479	$	52,014	$	11,769	$	-		$	167,262
Inter-segment revenues		351		447		355		(1,153	)		-
Segment operating income (loss)		31,462		14,419		3,484		2,323			51,688
Total assets		255,448		172,095		17,929		130,402			575,874
Capital expenditures		2,120		401		52		92			2,665
Depreciation and amortization		3,593		1,462		178		673			5,906
Six Months Ended June 30, 2010
Revenues from unaffiliated customers	$	210,621	$	148,561	$	28,057	$	-		$	387,239
Inter-segment revenues		548		713		715		(1,976	)		-
Segment operating income		50,215		47,095		9,292		(1,469	)		105,133
Total assets		258,759		190,512		14,245		189,145			652,661
Capital expenditures		9,929		1,392		257		1,118			12,696
Depreciation and amortization		7,030		3,249		324		917			11,520
Six Months Ended June 30, 2009
Revenues from unaffiliated customers	$	206,002	$	115,114	$	25,022	$	-		$	346,138
Inter-segment revenues		474		808		736		(2,018	)		-
Segment operating income (loss)		56,214		32,743		6,962		2,388			98,307
Total assets		255,448		172,095		17,929		130,402			575,874
Capital expenditures		4,183		988		52		97			5,320
Depreciation and amortization		6,950		2,924		355		1,385			11,614
(1) "Corporate & Other" represents those items that are not directly related to a particular segment and eliminations.

12. CONDENSED CONSOLIDATING FINANCIAL INFORMATION

Core Laboratories N.V. has fully and unconditionally guaranteed all of the Notes issued by Core Laboratories LP in 2006. Core Laboratories LP is a wholly owned subsidiary of Core Laboratories N.V.

The following condensed consolidating financial information is included so that separate financial statements of Core Laboratories LP are not required to be filed with the U.S. Securities and Exchange Commission (the "SEC"). The condensed consolidating financial statements present investments in both consolidated and unconsolidated affiliates using the equity method of accounting.

The following condensed consolidating financial information presents: balance sheets as of June 30, 2010 and December 31, 2009, statements of operations for each of the three and six months ended June 30, 2010 and 2009 and the statements of cash flows for each of the six months ended June 30, 2010 and 2009 of (a) Core Laboratories N.V., parent/guarantor, (b) Core Laboratories LP, issuer of public debt securities guaranteed by Core Laboratories N.V., (c) the non-guarantor subsidiaries, (d) consolidating adjustments necessary to consolidate Core Laboratories N.V. and its subsidiaries and (e) Core Laboratories N.V. on a consolidated basis.

11

Condensed Consolidating Balance Sheets (Unaudited)
(In thousands)	June 30, 2010
	Core Laboratories N.V. (Parent/ Guarantor)		Core Laboratories LP (Issuer)		Other Subsidiaries (Non- Guarantors)		Consolidating Adjustments			Consolidated Total
ASSETS
CURRENT ASSETS:
Cash and cash equivalents	$	32,379	$	127,184	$	14,059	$	-		$	173,622
Accounts receivable, net		1		30,072		107,492		-			137,565
Inventories, net		-		3,584		30,178		-			33,762
Prepaid expenses and other current assets		7,097		11,221		10,704		-			29,022
Total current assets		39,477		172,061		162,433		-			373,971
PROPERTY, PLANT AND EQUIPMENT, net		-		21,822		78,858		-			100,680
GOODWILL AND INTANGIBLES, net		46,986		16,275		100,147		-			163,408
INTERCOMPANY RECEIVABLES		-		261,797		329,159		(590,956	)		-
INVESTMENT IN AFFILIATES		609,764		-		1,731,110		(2,340,315	)		559
DEFERRED TAX ASSET		2,610		-		6,671		(9,281	)		-
OTHER ASSETS		2,670		8,835		2,538		-			14,043
TOTAL ASSETS	$	701,507	$	480,790	$	2,410,916	$	(2,940,552	)	$	652,661
LIABILITIES AND EQUITY
CURRENT LIABILITIES:
Accounts payable	$	193	$	7,177	$	32,158	$	-		$	39,528
Short-term debt		-		216,787		-		-			216,787
Other accrued expenses		2,111		26,534		52,452		-			81,097
Total current liabilities		2,304		250,498		84,610		-			337,412
LONG-TERM DEBT		-		-		-		-			-
DEFERRED COMPENSATION		6,352		11,695		96		-			18,143
DEFERRED TAX LIABILITY		-		17,520		-		(9,281	)		8,239
INTERCOMPANY PAYABLES		447,571		11,493		131,892		(590,956	)		-
OTHER LONG-TERM LIABILITIES		13,323		7,065		12,215		-			32,603
Equity Component of Short-term Debt - Senior Exchangeable Notes		-		21,871		-		-			21,871
SHAREHOLDERS' EQUITY		231,957		160,648		2,179,667		(2,340,315	)		231,957
NON-CONTROLLING INTEREST		-		-		2,436		-			2,436
TOTAL EQUITY		231,957		160,648		2,182,103		(2,340,315	)		234,393
TOTAL LIABILITIES AND EQUITY	$	701,507	$	480,790	$	2,410,916	$	(2,940,552	)	$	652,661

12

Condensed Consolidating Balance Sheets
(In thousands)	December 31, 2009
	Core Laboratories N.V. (Parent/ Guarantor)		Core Laboratories LP (Issuer)		Other Subsidiaries (Non- Guarantors)		Consolidating Adjustments			Consolidated Total
ASSETS
CURRENT ASSETS:
Cash and cash equivalents	$	73,998	$	95,048	$	11,999	$	-		$	181,045
Accounts receivable, net		1		29,452		104,305		-			133,758
Inventories, net		-		2,679		29,505		-			32,184
Prepaid expenses and other current assets		11,809		22,209		9,532		-			43,550
Total current assets		85,808		149,388		155,341		-			390,537
PROPERTY, PLANT AND EQUIPMENT, net		-		21,988		76,796		-			98,784
GOODWILL AND INTANGIBLES, net		46,986		7,949		100,185		-			155,120
INTERCOMPANY RECEIVABLES		37,681		216,670		232,802		(487,153	)		-
INVESTMENT IN AFFILIATES		540,724		-		1,387,715		(1,928,118	)		321
DEFERRED TAX ASSET		2,951		4,644		14,359		(21,954	)		-
OTHER ASSETS		2,828		8,770		1,806		-			13,404
TOTAL ASSETS	$	716,978	$	409,409	$	1,969,004	$	(2,437,225	)	$	658,166
LIABILITIES AND EQUITY
CURRENT LIABILITIES:
Accounts payable	$	501	$	6,404	$	26,104	$	-		$	33,009
Other accrued expenses		673		29,738		42,988		-			73,399
Total current liabilities		1,174		36,142		69,092		-			106,408
LONG-TERM DEBT		-		209,112		-		-			209,112
DEFERRED COMPENSATION		6,046		10,094		726		-			16,866
DEFERRED TAX LIABILITY		-		29,646		-		(21,954	)		7,692
INTERCOMPANY PAYABLES		417,618		-		69,535		(487,153	)		-
OTHER LONG-TERM LIABILITIES		12,772		7,702		15,856		-			36,330
SHAREHOLDERS' EQUITY		279,368		116,713		1,811,405		(1,928,118	)		279,368
NON-CONTROLLING INTEREST		-		-		2,390		-			2,390
TOTAL EQUITY		279,368		116,713		1,813,795		(1,928,118	)		281,758
TOTAL LIABILITIES AND EQUITY	$	716,978	$	409,409	$	1,969,004	$	(2,437,225	)	$	658,166

13

Condensed Consolidating Statements of Operations (Unaudited)
(In thousands)	Three Months Ended June, 2010
	Core Laboratories N.V. (Parent/ Guarantor)		Core Laboratories LP (Issuer)		Other Subsidiaries (Non- Guarantors)		Consolidating Adjustments			Consolidated Total
REVENUES
Operating revenues	$	-	$	48,386	$	150,516	$	-		$	198,902
Intercompany revenues		379		7,619		35,451		(43,449	)		-
Earnings from consolidated affiliates		37,709		-		115,745		(153,454	)		-
Total revenues		38,088		56,005		301,712		(196,903	)		198,902
OPERATING EXPENSES
Operating costs		322		25,237		103,358		-			128,917
General and administrative expenses		2,147		7,060		4		-			9,211
Depreciation and amortization		-		1,554		4,212		-			5,766
Other expense (income), net		992		3,411		29,884		(32,999	)		1,288
Operating income		34,627		18,743		164,254		(163,904	)		53,720
Interest expense		-		4,112		2		-			4,114
Income before income tax expense		34,627		14,631		164,252		(163,904	)		49,606
Income tax expense (benefit)		411		5,992		8,841		-			15,244
Net income		34,216		8,639		155,411		(163,904	)		34,362
Net income attributable to non-controlling interest		-		-		146		-			146
Net income attributable to Core Laboratories	$	34,216	$	8,639	$	155,265	$	(163,904	)	$	34,216

Condensed Consolidating Statements of Operations (Unaudited)
(In thousands)	Six Months Ended June 30, 2010
	Core Laboratories N.V. (Parent/ Guarantor)		Core Laboratories LP (Issuer)		Other Subsidiaries (Non- Guarantors)		Consolidating Adjustments			Consolidated Total
REVENUES
Operating revenues	$	-	$	93,547	$	293,692	$	-		$	387,239
Intercompany revenues		667		12,206		70,960		(83,833	)		-
Earnings from consolidated affiliates		72,898		-		216,504		(289,402	)		-
Total revenues		73,565		105,753		581,156		(373,235	)		387,239
OPERATING EXPENSES
Operating costs		712		50,221		203,572		-			254,505
General and administrative expenses		4,314		11,270		7		-			15,591
Depreciation and amortization		-		3,112		8,408		-			11,520
Other expense (income), net		857		5,002		58,192		(63,561	)		490
Operating income		67,682		36,148		310,977		(309,674	)		105,133
Interest expense		-		8,167		6		-			8,173
Income before income tax expense		67,682		27,981		310,971		(309,674	)		96,960
Income tax expense (benefit)		1,261		11,474		17,577		-			30,312
Net income		66,421		16,507		293,394		(309,674	)		66,648
Net income attributable to non-controlling interest		-		-		227		-			227
Net income attributable to Core Laboratories	$	66,421	$	16,507	$	293,167	$	(309,674	)	$	66,421

14

Condensed Consolidating Statements of Cash Flows (Unaudited)
(In thousands)	Six Months Ended June 30, 2010
	Core Laboratories N.V. (Parent/ Guarantor)			Core Laboratories LP (Issuer)			Other Subsidiaries (Non- Guarantors)			Consolidating Adjustments		Consolidated Total
Net cash provided by operating activities	$	54,349		$	44,964		$	12,047		$	-	$	111,360
CASH FLOWS FROM INVESTING ACTIVITIES:
Capital expenditures		-			(2,918	)		(9,778	)		-		(12,696	)
Patents and other intangibles		-			-			(142	)		-		(142	)
Acquisitions, net of cash		-			(9,000	)		-			-		(9,000	)
Proceeds from sale of assets		-			11			114			-		125
Premiums on life insurance		-			(921	)		-			-		(921	)
Net cash used in investing activities		-			(12,828	)		(9,806	)		-		(22,634	)
CASH FLOWS FROM FINANCING ACTIVITIES:
Stock options exercised		295			-			-			-		295
Excess tax benefit from stock-based payments		798			-			-			-		798
Non-controlling interest - dividends		-			-			(181	)		-		(181	)
Dividends paid		(5,375	)		-			-			-		(5,375	)
Repurchase of common shares		(91,686	)		-			-			-		(91,686	)
Net cash used in financing activities		(95,968	)		-			(181	)		-		(96,149	)
NET CHANGE IN CASH AND CASH EQUIVALENTS		(41,619	)		32,136			2,060			-		(7,423	)
CASH AND CASH EQUIVALENTS, beginning of period		73,998			95,048			11,999			-		181,045
CASH AND CASH EQUIVALENTS, end of period	$	32,379		$	127,184		$	14,059		$	-	$	173,622

Condensed Consolidating Statements of Operations (Unaudited)
(In thousands)	Three Months Ended June 30, 2009
	Core Laboratories N.V. (Parent/ Guarantor)			Core Laboratories LP (Issuer)		Other Subsidiaries (Non- Guarantors)		Consolidating Adjustments			Consolidated Total
REVENUES
Operating revenues	$	-		$	40,675	$	126,587	$	-		$	167,262
Intercompany revenues		355			6,758		19,745		(26,858	)		-
Earnings from consolidated affiliates		33,141			-		93,831		(126,972	)		-
Total revenues		33,496			47,433		240,163		(153,830	)		167,262
OPERATING EXPENSES
Operating costs		308			21,426		87,263		-			108,997
General and administrative expenses		1,992			4,689		3		-			6,684
Depreciation and amortization		-			1,379		4,527		-			5,906
Other expense (income), net		(3,282	)		3,499		24,454		(30,684	)		(6,013	)
Operating income		34,478			16,440		123,916		(123,146	)		51,688
Interest expense		418			3,411		11		-			3,840
Income before income tax expense		34,060			13,029		123,905		(123,146	)		47,848
Income tax expense (benefit)		4,253			6,652		6,979		-			17,884
Net income		29,807			6,377		116,926		(123,146	)		29,964
Net income attributable to non-controlling interest		-			-		157		-			157
Net income attributable to Core Laboratories	$	29,807		$	6,377	$	116,769	$	(123,146	)	$	29,807

15

Condensed Consolidating Statements of Operations (Unaudited)
(In thousands)	Six Months Ended June 30, 2009
	Core Laboratories N.V. (Parent/ Guarantor)			Core Laboratories LP (Issuer)		Other Subsidiaries (Non- Guarantors)		Consolidating Adjustments			Consolidated Total
REVENUES
Operating revenues	$	-		$	85,809	$	260,329	$	-		$	346,138
Intercompany revenues		698			13,357		49,745		(63,800	)		-
Earnings from consolidated affiliates		63,428			-		186,484		(249,912	)		-
Total revenues		64,126			99,166		496,558		(313,712	)		346,138
OPERATING EXPENSES
Operating costs		620			45,031		179,378		-			225,029
General and administrative expenses		5,452			10,499		7		-			15,958
Depreciation and amortization		-			2,748		8,866		-			11,614
Other expense (income), net		(3,293	)		7,634		52,022		(61,133	)		(4,770	)
Operating income		61,347			33,254		256,285		(252,579	)		98,307
Interest expense		893			6,716		31		-			7,640
Income before income tax expense		60,454			26,538		256,254		(252,579	)		90,667
Income tax expense (benefit)		1,455			11,438		18,571		-			31,464
Net income		58,999			15,100		237,683		(252,579	)		59,203
Net income attributable to non-controlling interest		-			-		204		-			204
Net income attributable to Core Laboratories	$	58,999		$	15,100	$	237,479	$	(252,579	)	$	58,999

Condensed Consolidating Statements of Cash Flows (Unaudited)
(In thousands)	Six Months Ended June 30, 2009
	Core Laboratories N.V. (Parent/ Guarantor)			Core Laboratories LP (Issuer)			Other Subsidiaries (Non- Guarantors)			Consolidating Adjustments		Consolidated Total
Net cash provided by operating activities	$	39,495		$	39,163		$	7,609		$	-	$	86,267
CASH FLOWS FROM INVESTING ACTIVITIES:
Capital expenditures		-			(1,022	)		(4,298	)		-		(5,320	)
Patents and other intangibles		-			-			(151	)		-		(151	)
Proceeds from sale of assets		-			175			284			-		459
Premiums on life insurance		-			(844	)		-			-		(844	)
Net cash used in investing activities		-			(1,691	)		(4,165	)		-		(5,856	)
CASH FLOWS FROM FINANCING ACTIVITIES:
Stock options exercised		302			-			-			-		302
Excess tax benefit from stock-based payments		127			-			-			-		127
Non-controlling interest - dividends		-			-			(246	)		-		(246	)
Dividends paid		(4,597	)		-			-			-		(4,597	)
Repurchase of common shares		(8,889	)		-			-			-		(8,889	)
Net cash used in financing activities		(13,057	)		-			(246	)		-		(13,303	)
NET CHANGE IN CASH AND CASH    EQUIVALENTS		26,438			37,472			3,198			-		67,108
CASH AND CASH EQUIVALENTS,    beginning of period		13,347			11,027			11,764			-		36,138
CASH AND CASH EQUIVALENTS,    end of period	$	39,785		$	48,499		$	14,962		$	-	$	103,246

16

Item 2. Management's Discussion and Analysis of Financial Condition and Results of Operations

The following discussion summarizes the financial position of Core Laboratories N.V. and its subsidiaries as of June 30, 2010 and should be read in conjunction with (i) the unaudited consolidated interim financial statements and notes thereto included elsewhere in this Quarterly Report on Form 10-Q and (ii) the consolidated financial statements and accompanying notes to our Annual Report on Form 10-K for the fiscal year ended December 31, 2009.

General

Core Laboratories N.V. is a Netherlands limited liability company.  It was established in 1936 and is one of the world's leading providers of proprietary and patented reservoir description, production enhancement and reservoir management products and services to the oil and gas industry.  These products and services can enable our clients to improve reservoir performance and increase oil and gas recovery from their producing fields.  Core Laboratories N.V. has over 70 offices in more than 50 countries and employs approximately 5,000 people worldwide.

References to "Core Lab", "we", "our" and similar phrases are used throughout this Quarterly Report on Form 10-Q and relate collectively to Core Laboratories N.V. and its consolidated affiliates.

Our business units have been aggregated into three complementary segments, which provide products and services for improving reservoir performance and increasing oil and gas recovery from new and existing fields.

*	Reservoir Description: Encompasses the characterization of petroleum reservoir rock, fluid and gas samples. We provide analytical and field services to characterize properties of crude oil and petroleum products to the oil and gas industry.
*	Production Enhancement: Includes products and services relating to reservoir well completions, perforations, stimulations and production. We provide integrated services to evaluate the effectiveness of well completions and to develop solutions aimed at increasing the effectiveness of enhanced oil recovery projects.
*	Reservoir Management: Combines and integrates information from reservoir description and production enhancement services to increase production and improve recovery of oil and gas from our clients' reservoirs.

Cautionary Statement Regarding Forward-Looking Statements

This Quarterly Report on Form 10-Q contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Certain statements contained in this Management's Discussion and Analysis of Financial Condition and Results of Operations section, including those under the headings "Outlook" and "Liquidity and Capital Resources", and in other parts of this Form 10-Q, are forward-looking. In addition, from time to time, we may publish forward-looking statements relating to such matters as anticipated financial performance, business prospects, technological developments, new products, research and development activities and similar matters. Forward-looking statements can be identified by the use of forward-looking terminology such as "may", "will", "believe", "expect ", "anticipate", "estimate", "continue", or other similar words, including statements as to the intent, belief, or current expectations of our directors, officers, and management with respect to our future operations, performance, or positions or which contain other forward-looking information. These forward-looking statements are based on our current expectations and beliefs concerning future developments and their potential effect on us. While management believes that these forward-looking statements are reasonable as and when made, no assurances can be given that the future results indicated, whether expressed or implied, will be achieved. Our actual results may differ significantly from the results discussed in the forward-looking statements. While we believe that these statements are and will be accurate, a variety of factors could cause our actual results and experience to differ materially from the anticipated results or other expectations expressed in our statements. Such factors include, but are not limited to, the risks and uncertainties summarized below:

- general and economic business conditions;

- market prices of oil and gas and expectations about future prices;

- cost of producing oil and natural gas;

- the level of drilling and production activity;

- mergers, consolidations and downsizing among our clients;

- coordination by OPEC;

17

- the impact of commodity prices on the expenditure levels of our clients;

- financial condition of our client base and their ability to fund capital expenditures;

- the physical and/or financial effects of climatic change, including adverse weather or geologic/geophysical conditions;

- the adoption of legal requirements or taxation relating to climate change that lower the demand for petroleum-based fuels;

- civil unrest in oil producing or consuming countries;

- level of consumption of oil, gas and petrochemicals by consumers;

- changes in existing laws, regulations, or other governmental actions;

- the business opportunities (or lack thereof) that may be presented to and pursued by us; and

- availability of services and materials for our clients to grow their capital expenditures.

Should one or more of these risks or uncertainties materialize, or should any of our assumptions prove incorrect, actual results may vary in material respects from those projected in the forward-looking statements. We undertake no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise. For a more detailed discussion of some of the foregoing risks and uncertainties, see "Item 1A - Risk Factors" in our Annual Report on Form 10-K for the fiscal year ended December 31, 2009, as well as the other reports filed by us with the Securities and Exchange Commission (“SEC”).

Outlook

We continue our efforts to expand our market presence by opening facilities in strategic areas and realizing synergies within our business lines.  We believe our market presence provides us a unique opportunity to service customers who have global operations in addition to the national oil companies.

We have established internal earnings targets that are based on market conditions existing at the time our targets were established.  Based on recent developments, we believe that the current level of activities, workflows, and operating margins outside North America will grow at moderate rates and that North American onshore activity will also grow at moderate rates.  Deepwater activity in the Gulf of Mexico is currently suspended by US governmental decree.

18

Results of Operations

Our results of operations as a percentage of applicable revenue were as follows (in thousands):

(Unaudited)	Three Months Ended June 30,									% Change
	2010				2009						2010/2009
REVENUES:
Services	$	153,010	77	%	$	134,671		81	%		14	%
Product sales		45,892	23	%		32,591		19	%		41	%
Total revenues		198,902	100	%		167,262		100	%		19	%
OPERATING EXPENSES:
Cost of services*		96,411	63	%		84,401		63	%		14	%
Cost of product sales*		32,506	71	%		24,596		75	%		32	%
Total cost of services and product sales		128,917	65	%		108,997		65	%		18	%
General and administrative expenses		9,211	4	%		6,684		4	%		38	%
Depreciation and amortization		5,766	3	%		5,906		4	%		(2	%)
Other expense (income), net		1,288	1	%		(6,013	)	(4	%)		(121	%)
Operating income		53,720	27	%		51,688		31	%		4	%
Interest expense		4,114	2	%		3,840		2	%		7	%
Income before income tax expense		49,606	25	%		47,848		29	%		4	%
Income tax expense		15,244	8	%		17,884		11	%		(15	%)
Net income		34,362	17	%		29,964		18	%		15	%
Net income attributable to non-controlling interest		146	-			157		-			(7	%)
Net income attributable to Core Laboratories N.V.	$	34,216	17	%	$	29,807		18	%		15	%
*Percentage based on applicable revenue rather than total revenue

(Unaudited)	Six Months Ended June 30,									% Change
	2010				2009						2010/2009
REVENUES:
Services	$	296,452	77	%	$	276,363		80	%		7	%
Product sales		90,787	23	%		69,775		20	%		30	%
Total revenues		387,239	100	%		346,138		100	%		12	%
OPERATING EXPENSES:
Cost of services*		191,768	65	%		172,697		62	%		11	%
Cost of sales*		62,737	69	%		52,332		75	%		20	%
Total cost of services and sales		254,505	66	%		225,029		65	%		13	%
General and administrative expenses		15,591	4	%		15,958		5	%		(2	%)
Depreciation and amortization		11,520	3	%		11,614		3	%		(1	%)
Other expense, net		490	-			(4,770	)	(1	%)		(110	%)
Operating income		105,133	27	%		98,307		28	%		7	%
Interest expense		8,173	2	%		7,640		2	%		7	%
Income before income tax expense		96,960	25	%		90,667		26	%		7	%
Income tax expense		30,312	8	%		31,464		9	%		(4	%)
Net income		66,648	17	%		59,203		17	%		13	%
Net income attributable to non-controlling interest		227	-			204		-			11	%
Net income attributable to Core Laboratories N.V.	$	66,421	17	%	$	58,999		17	%		13	%
*Percentage based on applicable revenue rather than total revenue

19

Operating Results for the Three and Six Months Ended June 30, 2010 Compared to the Three and Six Months Ended June 30, 2009 (unaudited)

Service Revenues

Service revenues increased to $153.0 million for the second quarter of 2010, up 14% when compared to $134.7 million for the second quarter of 2009. For the six months ended June 30, 2010, service revenues increased 7% to $296.5 million compared to $276.4 million for the respective period in 2009.  The increase in service revenues was due, in part, to the increased demand for reservoir fluids phase-behavior studies, and for crude oil testing, inspection, distillation, assay, fractionation and characterization projects worldwide.  Our large scale core analyses and advance rock properties studies from the eastern Mediterranean region, the Middle East, and both South Atlantic offshore margins also provided meaningful revenue streams.  Activity in North American Gas Shale plays has accelerated in the first half of 2010 leading to growth in stimulation related projects.

Product Sales Revenues

Revenues associated with product sales increased to $45.9 million for the second quarter of 2010, up 41% from $32.6 million for the second quarter of 2009. For the six months ended June 30, 2010, product sale revenues increased 30% to $90.8 million compared to $69.8 million for the same period in 2009. The increase in revenue was driven by the acceptance and demand of our specialized completion products introduced over the last three years and has led to increased market share in North American natural gas and oil shale reservoirs and has increased market penetration in Middle East and Asia-Pacific perforating markets.  These specialized optimizing technologies are focused on high-end well completion and stimulation programs mainly in the Haynesville, Marcellus, Montney and Eagle Ford shale plays and in multi-stage completions i n the Bakken oil-shale play. We are also providing high margin completion and recompletion technologies and services to be used in reworking major, giant, and super giant fields in southern Iraq.

Cost of Services

Cost of services expressed as a percentage of service revenue was 63% for the quarter ended June 30, 2010, which was unchanged from the same period in 2009.  For the six months ended June 30, 2010, cost of services expressed as a percentage of service revenue was 65% as compared to 62% for the same period in 2009.  The increase in the cost of services relative to service revenue was primarily a result of slightly higher sales of lower margins services.

Cost of Product Sales

Cost of sales as a percentage of product sales revenues was 71% for the quarter ended June 30, 2010, down from 75% for the same period in 2009. For the six months ended June 30, 2010, cost of product sales expressed as a percentage of sales revenue was 69%, down from 75% for the same period in 2009. The decrease in cost of sales as a percentage of product sale revenues was primarily due to the growing demand for our new technologies which are our higher margin products and from an overall increase in sales which improved absorption of our fixed cost structure and increased manufacturing efficiencies with the increased volume of product sales.

General and Administrative Expenses

General and administrative expenses totaled $9.2 million for the second quarter of 2010, up 38% from the $6.7 million incurred in the second quarter of 2009 due to compensation related expenses and additional facilities maintenance expenses. For the six months ended June 30, 2010 and 2009, general and administrative expenses were comparable at $15.6 million and $16.0 million, respectively.

Depreciation and Amortization Expense

Depreciation and amortization expense decreased to $5.8 million for the second quarter of 2010, down 2% when compared to $5.9 million for the second quarter of 2009.  For the six months ended June 30, 2010, depreciation and amortization expense was $11.5 million, a decrease of $0.1 million from the six months ended June 30, 2009.

20

Other Expense (Income), Net

Other expense (income), net consisted of the following for the quarter ended June 30, 2010 and 2009 (in thousands):

	Three Months Ended June 30,						Six Months Ended June 30,
	2010			2009			2010			2009
	(Unaudited)						(Unaudited)
Gain on sale of assets	$	39		$	(268	)	$	8		$	(345	)
Foreign exchange loss (gain)		1,712			(2,897	)		1,621			(1,009	)
Interest income		(130	)		(59	)		(142	)		(98	)
Non-income tax accrual		-			(2,500	)		-			(2,500	)
Rents and royalties		(218	)		(508	)		(700	)		(849	)
Other, net		(115	)		219			(297	)		31
Total other expense (income), net	$	1,288		$	(6,013	)	$	490		$	(4,770	)

As a result of finalizing a non-income related tax settlement agreement, we released the remaining $2.5 million of the contingent liability during the second quarter of 2009.

Foreign exchange losses (gains) by currency are summarized in the following table (in thousands):

	Three Months Ended June 30,						Six Months Ended June 30,
	2010			2009			2010			2009
	(Unaudited)						(Unaudited)
Australian Dollar	$	103		$	(300	)	$	103		$	(278	)
British Pound		158			(304	)		416			(232	)
Canadian Dollar		149			(1,115	)		(236	)		(767	)
Euro		1,619			(376	)		1,589			(213	)
Russian Ruble		(69	)		(372	)		(15	)		224
Venezuelan Bolivar		(202	)		(1	)		(191	)		(1	)
Other currencies, net		(46	)		(429	)		(45	)		258
Total loss (gain)	$	1,712		$	(2,897	)	$	1,621		$	(1,009	)

Income Tax Expense

The effective tax rates for the three months ended June 30, 2010 and 2009 were 30.7% and 37.4%, respectively.  The higher effective tax rate for 2009 was due primarily to a write down of assets in Venezuela without a tax benefit in the second quarter of last year.

Segment Analysis

Our operations are managed primarily in three complementary segments - Reservoir Description, Production Enhancement and Reservoir Management.  The following tables summarize our results by operating segment for the three months ended June 30, 2010 and 2009 (in thousands):

21

	Three Months Ended June 30,					% Change
	2010			2009			2010/2009
Revenues:	(Unaudited)
Reservoir Description	$	106,528		$	103,479		3	%
Production Enhancement		79,717			52,014		53	%
Reservoir Management		12,657			11,769		8	%
Consolidated	$	198,902		$	167,262		19	%
Operating income:
Reservoir Description	$	25,074		$	31,462		(20	%)
Production Enhancement		26,152			14,419		81	%
Reservoir Management		3,672			3,484		5	%
Corporate and Other1		(1,178	)		2,323	NM
Consolidated	$	53,720		$	51,688		4	%
(1) "Corporate and Other" represents those items that are not directly related to a particular segment
"NM"  means not meaningful

	Six Months Ended June 30,					% Change
	2010			2009			2010/2009
Revenues:	(Unaudited)
Reservoir Description	$	210,621		$	206,002		2	%
Production Enhancement		148,561			115,114		29	%
Reservoir Management		28,057			25,022		12	%
Consolidated	$	387,239		$	346,138		12	%
Operating income:
Reservoir Description	$	50,215		$	56,214		(11	%)
Production Enhancement		47,095			32,743		44	%
Reservoir Management		9,292			6,962		33	%
Corporate and Other1		(1,469	)		2,388	NM
Consolidated	$	105,133		$	98,307		7	%
(1) "Corporate and Other" represents those items that are not directly related to a particular segment
"NM"  means not meaningful

Reservoir Description

Revenues from the Reservoir Description segment increased 3%, or $3.0 million, to $106.5 million in the second quarter of 2010, compared to $103.5 million in the second quarter of 2009.  For the six months ended June 30, 2010, revenues increased 2%, or $4.6 million, to $210.6 million from $206.0 million for the six months ended June 30, 2009. This segment’s operations continued to benefit from large-scale core analyses and advanced rock properties studies from the eastern Mediterranean region, the Middle East and both South Atlantic offshore margins.  This segment continued to realize increased demand for reservoir fluids phase-behavior studies, and for crude oil testing, inspection, distillation, assay, fractionation and characterization projects worldwide.

Operating income in the second quarter of 2010 decreased by 20%, or $6.4 million, to $25.1 million compared to $31.5 million for the second quarter of 2009.  Operating income for the six months ended June 30, 2010 decreased by 11%, or $6.0 million, to $50.2 million.  Operating margins for the quarter and six months ended June 30, 2010 were 24% for both periods, compared to 30% and 27% for the same periods in 2009, respectively. This segment continues to focus on emphasizing higher value, and thus higher margin, services on internationally-based development and production-related crude oil projects in addition to de-emphasizing the more cyclical exploration-related projects.  As a result of the industry slow-down experienced in 2009, we de layed implementing certain compensation programs in an effort to reduce our cost structure. Those programs were instituted in the first half of 2010 which increased our cost structure without the benefit of a corresponding increase in revenue. 

22

Production Enhancement

Revenues from the Production Enhancement segment increased by 53%, or $27.7 million, to $79.7 million in the second quarter of 2010 as compared to $52.0 million in the second quarter of 2009. Revenues increased by 29%, or $33.5 million, to $148.6 million for the six months ended June 30, 2010 as compared to $115.1 million for the same period in 2009.  The revenue increase was due to the increased acceptance by our clients of our high margin completion products as well as our fracture diagnostic services, and an increased market share of our perforating charges and gun systems particularly in the North American natural gas market.

Operating income in the second quarter of 2010 increased by 81%, or $11.8 million, to $26.2 million from $14.4 million for the second quarter of 2009.  Operating margins increased to 33% in the second quarter of 2010 compared to 28% for the same period in 2009.  For the six months ended June 30, 2010, operating income increased to $47.1 million, an increase of 44% over the same period in 2009.  The increase in margins was primarily driven by our continued market penetration of higher-margin services including our proprietary and patented diagnostic technologies, such as SpectraChem® Plus+, SpectraScan®, ZeroWash®, and our HERO™ line of perforating charges and gun systems.  This segment also began providing high margin completion and recompletion technologies and services to be used in the reworking of major, giant, and super giant fields in southern Iraq.

Reservoir Management

Revenues from the Reservoir Management segment increased by 8% in the second quarter of 2010 compared to the second quarter of 2009.  Revenues for the six months ended June 30, 2010 were $28.1 million, an increase of 12% from $25.0 million from the same period in 2009. The increase in revenue was due to ongoing interest in several of our existing multi-client reservoir studies including studies in the Montney Shale in northeastern British Columbia and northern Alberta, and the Eagle Ford Shale in south Texas, along with the continued participation in our North American Gas Shale Study.  In addition, increased revenue was provided by our proprietary studies which parallel our joint-industry projects, including studies of offshore Ivory Coast and Nigeria and a gas-shale reconnaissance project in Indonesia.

Operating income in the second quarter of 2010 increased 5% to $3.7 million from $3.5 million for the second quarter of 2009. For the six months ended June 30, 2010, operating income was $9.3 million, compared to operating income of $7.0 million from the same period in 2009. The increase in operating income was primarily related to growth in our consortium projects and the timing of our analysis work on these projects.

Liquidity and Capital Resources

General

We have historically financed our activities through cash on hand, cash flows from operations, bank credit facilities, or the issuance of debt and equity financing.

We utilize the non-GAAP financial measure of free cash flow to evaluate our cash flows and results of operations.  Free cash flow is defined as net cash provided by operating activities (which is the most directly comparable GAAP measure) less capital expenditures.  Management believes that free cash flow provides useful information to investors regarding the cash that was available in the period that was in excess of our needs to fund our capital expenditures and operating activities. Free cash flow is not a measure of operating performance under GAAP, and should not be considered in isolation nor construed as an alternative to operating profit, net income (loss) or cash flows from operating, investing or financing activities, each as determined in accordance with GAAP. Free cash flow does not represent residual cash available for distribution because we may have other non-discretionary expenditures that are not deducted from the measure. Moreover, since free cash flow is not a measure determined in accordance with GAAP and thus is susceptible to varying interpretations and calculations, free cash flow as presented, may not be comparable to similarly titled measures presented by other companies.  The following table reconciles this non-GAAP financial measure to the most directly comparable measure calculated and presented in accordance with GAAP for the six months ended June 30, 2010 and 2009 (in thousands):

23

	Six Months Ended June 30,				% Change
	2010		2009			2010/2009
Free cash flow calculation:	(Unaudited)
Net cash provided by operating activities	$	111,360	$	86,267		29	%
Less:  capital expenditures		12,696		5,320		139	%
Free cash flow	$	98,664	$	80,947		22	%

The increase in free cash flow in 2010 compared to 2009 was due to an increase in net income and improved working capital excluding cash and senior exchangeable notes, primarily from the utilization of income tax receivables.

Cash Flows

The following table summarizes cash flows for the six months ended June 30, 2010 and 2009 (in thousands):

	Six Months Ended June 30,						% Change
	2010			2009				2010/2009
Cash provided by/(used in):	(Unaudited)
Operating activities	$	111,360		$	86,267			29	%
Investing activities		(22,634	)		(5,856	)		287	%
Financing activities		(96,149	)		(13,303	)		623	%
Net change in cash and cash equivalents	$	(7,423	)	$	67,108			(111	%)

The increase in cash flows provided by operating activities was primarily attributable to an increase in net income and improved working capital excluding cash and senior exchangeable notes, due to the realization of income tax receivables.

Cash flows used in investing activities increased due to higher capital expenditures of $12.7 million for the period and an acquisition for $9.0 million.

The increase in cash flows used in financing activities relates primarily to an increase in the number of shares repurchased under our common share repurchase program.  In the first six months of 2010, we repurchased 1,483,280 shares for an aggregate price of $91.7 million compared to 268,648 shares for an aggregate price of $8.9 million during the same period in 2009.

In 2006, Core Laboratories LP, a wholly owned subsidiary of Core Laboratories N.V., issued $300 million aggregate principal amount of Senior Exchangeable Notes (the "Notes") which are fully and unconditionally guaranteed by Core Laboratories N.V. and mature on October 31, 2011.

Under the terms of the Notes, on June 30, 2010, the early exchange option for the holders of the Notes was enabled. As a result, the Notes can be exchanged during the third quarter of 2010 and will remain classified as a short-term liability.  On March 31, 2010, the early exchange option was enabled allowing the holders of the Notes to exchange them during the second quarter of 2010.  We received six requests during the second quarter of 2010 to exchange 28 Notes.

We maintain a revolving credit facility (the "Credit Facility") that allows for an aggregate borrowing capacity of $100.0 million. The Credit Facility provides an option to increase the commitment under the Credit Facility to $150.0 million, if certain conditions are met.  The Credit Facility bears interest at variable rates from LIBOR plus 0.5% to a maximum of LIBOR plus 1.125%.  Any outstanding balance under the Credit Facility is due in December 2010 when the Credit Facility matures.  Interest payment terms are variable depending upon the specific type of borrowing under this facility. Our available borrowing capacity under the Credit Facility is reduced by outstanding letters of credit and performance guarantees and bonds arranged under the Credit Facility which totaled $12.6 million at June 30, 2010 and related to certain projects in progress.  Our available borrowing capacity under the Credit Facility at June 30, 2010 was $87.4 million. As of June 30, 2010, we had $14.9 million of outstanding letters of credit and performance guarantees and bonds in addition to those under the Credit Facility.

The terms of the Credit Facility require us to meet certain financial and operational covenants. We believe that we were in compliance with all such covenants at June 30, 2010.  All of our material, wholly owned subsidiaries are guarantors or co-borrowers under the Credit Facility.

24

Our ability to maintain and grow our operating income and cash flow depends, to a large extent, on continued investing activities. We are a Netherlands holding company and substantially all of our operations are conducted through subsidiaries. Consequently, our cash flow depends upon the ability of our subsidiaries to pay cash dividends or otherwise distribute or advance funds to us.  We believe our future cash flows from operations, supplemented by our borrowing capacity and issuances of additional equity should be sufficient to fund our debt requirements, capital expenditures, working capital, dividend payments and future acquisitions.

Item 3. Quantitative and Qualitative Disclosures About Market Risk

There have been no material changes in market risk from the information provided in Item 7A. "Quantitative and Qualitative Disclosures About Market Risk" in our Annual Report on Form 10-K for the fiscal year ended December 31, 2009.

Item 4. Controls and Procedures

A complete discussion of our controls and procedures is included in our Annual Report on Form 10-K for the year ended December 31, 2009.

Disclosure Controls and Procedures

Our management, under the supervision of and with the participation of our Chief Executive Officer and Chief Financial Officer, has evaluated the effectiveness of our disclosure controls and procedures, as such term is defined in Rules 13a-15(e) and 15d-15(e) under the Securities Exchange Act of 1934, as amended (the "Exchange Act"), as of the end of the period covered by this report.  Our disclosure controls and procedures are designed to provide reasonable assurance that the information required to be disclosed by us in our reports filed or submitted under the Exchange Act is accumulated and communicated to management, including our Chief Executive Officer and Chief Financial Officer, as appropriate, to allow timely decisions regarding required disclosure and is recorded, processed, summarized and reported within the time peri ods specified in the rules and forms of the SEC.  Based on such evaluation, our Chief Executive Officer and Chief Financial Officer have concluded that our disclosure controls and procedures were effective as of June 30, 2010 at the reasonable assurance level.

Our management does not expect that our disclosure controls and procedures or our internal control over financial reporting will prevent all errors and all fraud.  Further, the design of disclosure controls and internal control over financial reporting must reflect the fact that there are resource constraints, and the benefits of controls must be considered relative to their costs.  Because of the inherent limitations in all control systems, no evaluation of controls can provide absolute assurance that all control issues and instances of fraud, if any, within a company have been detected.

Changes in Internal Control Over Financial Reporting

There have been no changes in our system of internal control over financial reporting, as such term is defined in Rules 13a-15(f) and 15d-15(f) under the Exchange Act, during our fiscal quarter ended June 30, 2010, that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.

25

CORE LABORATORIES N.V.

PART II - OTHER INFORMATION

Item 1.  Legal Proceedings

See Note 6 of Consolidated Interim Financial Statements in Part I, Item 1.

Item 2.  Unregistered Sales of Equity Securities and Use of Proceeds

The following table provides information about purchases of equity securities that are registered by us pursuant to Section 12 of the Exchange Act during the quarter ended June 30, 2010:

Period	Total Number of Shares Purchased		Average Price Paid Per Share		Total Number of Shares Purchased as Part of a Publicly Announced Program		Maximum Number of Shares That May Yet be Purchased Under the Program (4)
April 1-30, 2010 (1)		11,232	$	66.56		11,232		6,678,359
May 1-31, 2010 (2)		53,178		68.74		53,178		6,671,481
June 1-30, 2010 (3)		11,066		73.78		11,066		6,702,213
Total		75,476	$	69.15		75,476

(1) Contains 11,232 shares valued at approximately $0.7 million, or $66.56 per share, surrendered to us by participants in a stock-based compensation plan to settle any personal tax liabilities which may result from the award in April 2010.

(2) Contains 13,178 shares valued at approximately $0.9 million, or $70.27 per share, surrendered to us by participants in a stock-based compensation plan to settle any personal tax liabilities which may result from the award in May 2010.

(3) Contains 11,066 shares valued at approximately $0.8 million, or $73.78 per share, surrendered to us by participants in a stock-based compensation plan to settle any personal tax liabilities which may result from the award in June 2010.

(4) In connection with our initial public offering in September 1995, our shareholders authorized our Management Board to repurchase up to 10% of our issued share capital, the maximum allowed under Dutch law at the time, for a period of 18 months.  This authorization was renewed at subsequent annual or special shareholder meetings.  At our annual shareholders’ meeting on June 10, 2010, following a change in Dutch law that permitted us to repurchase up to 50% of our issued share capital in open market purchases, subject to shareholder approval, our shareholders authorized an extension through December 10, 2011 to purchase up to 25.6% of our issued share capital, consisting of 10% of our issued shares and an additional 15.6% of our issued shares to fulfill obligations relating to the Notes or warrants. The repurcha se of shares in the open market is at the discretion of management pursuant to this shareholder authorization.

26

Exhibit No.		Exhibit Title	Incorporated by reference from the following documents
3.1	-	Articles of Association of Core Laboratories N.V., as amended (including English translation)	Filed herewith
31.1	-	Certification of Chief Executive Officer Pursuant to Rule 13a-14(a) of the Securities Exchange Act of 1934, as Adopted Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002	Filed herewith
31.2	-	Certification of Chief Financial Officer Pursuant to Rule 13a-14(a) of the Securities Exchange Act of 1934, as Adopted Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002	Filed herewith
32.1	-	Certification of Chief Executive Officer Pursuant to 18 U.S.C. Section 1350, as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002	Furnished herewith
32.2	-	Certification of Chief Financial Officer Pursuant to 18 U.S.C. Section 1350, as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002	Furnished herewith

27

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant, Core Laboratories N.V., has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

		CORE LABORATORIES N.V.
		By:	Core Laboratories International B.V., its
			Managing Director
Date:	July 23, 2010	By:	/s/ Richard L. Bergmark
			Richard L. Bergmark
			Chief Financial Officer
			(Duly Authorized Officer and
			Principal Financial Officer)

28

EX-3.1

1

NautaDutilh N.V.

CONTINUOUS TEXT of the articles of association of Core Laboratories N.V., with corporate seat in Amsterdam, after partial amendment to the articles of association, by deed executed before M.D.P. Anker, civil law notary in Amsterdam, on 8 July 2010.

Ministerial declaration of no-objection dated 18 June 2010, number N.V. 495,252.

This is a translation into English of the original Dutch text. An attempt has been made to be as literal as possible without jeopardizing the overall continuity. Inevitably, differences may occur in translation, and if so the Dutch text will by law govern.

_____________________________________________________________________

ARTICLES OF ASSOCIATION

DEFINITIONS

Article 1.

The terms used in the Articles of Association of this company are defined below:

a. the company: the legal entity to which these Articles of Association appertain;

b. the board of management: the management board of the company;

c. the board of supervisory directors: the board of supervisory directors of the company;

d. rights attached to depositary receipts for shares: the rights which the (Dutch) Civil Code grants to holders of depositary receipts for shares which have been issued with the cooperation of a company;

e. persons entitled to attend meetings: the company's shareholders, usufructuaries and pledgees holding the rights attached to depositary receipts for shares of the company;

f. the general meeting: either the body that comprises the voting shareholders of the company and other persons within the company entitled to vote or the meeting of persons entitled to attend meetings of the shareholders of the company;

g. the meeting of holders of shares of a special class: either the body that comprises the persons holding the voting rights over shares of a special class or the meeting of persons holding the voting rights over shares of a special class;

h. distributable reserves: that part of the company's equity which exceeds the sum of the paid and called-up capital and the reserves which have to be maintained by virtue of the law and/or these Articles of Association;

i. annual accounts: the balance sheet, the profit and loss account and explanatory notes to these documents;

j. subsidiary: a legal entity

(a) in the general meeting of which the company or one or more of its subsidiaries can, whether or not by virtue of an agreement with other persons entitled to vote, exercise on its own or together with others more than half of the voting rights or

(b) of which the company or one or more of its subsidiaries is or are a shareholder and in which it or they can, whether or not by virtue of an agreement with other persons entitled to vote, appoint or dismiss on its own or together with others more than half of the managing or supervisory directors, even if all those entitled to vote do so, as well as other legal entities which the

82035180 M 3748240 / 1

1

law equates with subsidiaries, all the aforegoing within the meaning of article 2:24a of the (Dutch) Civil Code;

k. group company: a legal entity with which the company is structurally associated into an economic unity.

NAME, CORPORATE SEAT, DURATION

Article 2.

1. The name of the company is: Core Laboratories N.V..

2. It has its corporate seat at Amsterdam.

3. The company shall continue to exist for an indefinite period of time.

OBJECTS

Article 3.

The objects of the company are:

1. the acquisition, possession, administration, sale, exchange, transfer and investment in and disposal of shares, bonds, funds, order documents, evidences of indebtedness and other securities, the borrowing of money and the issuance of documents evidencing indebtedness therefor, as well as the lending of money;

2. the granting of suretyships for the fulfilment of obligations of the company or of third parties;

3. The acquisition of:

a. income arising from the disposal or licensing of copyrights, patents, designs, secret processes or formulae, trademarks and similar interests;

b. royalties, including rentals, in respect of or relating to the use of industrial, commercial or scientific equipment as well as in respect of the exploitation of a mine or quarry or any other natural resource and other real properties;

c. consideration for the rendering of technical assistance and scientific analyses and related services;

4. the acquisition, possession, disposal, administration, development, lease, letting, mortgaging or in general the encumbrance of real property and any right to or interest in real property;

5. the trading in, including wholesale, distributive and future trade, the manufacturing, as well as the import and export of raw materials, minerals, metals, organic materials, semi-finished products and finished products of whatever nature and under whatever name;

6. the acting as a holding company;

7. the participation in and the management and joint management of other companies and enterprises; and

8. the performance of everything connected with the foregoing in the widest sense of the word.

SHARE CAPITAL, SHARES, DEPOSITARY RECEIPTS

Article 4.

1. The authorised share capital of the company amounts to four million one hundred twenty thousand euros (EUR 4,120,000.--), divided into two hundred million (200,000,000) ordinary shares and six million (6,000,000) preference shares, each with a nominal value of two eurocents (EUR 0.02).

2. The common shares and the preference shares shall be in registered form only.

3. Where in these Articles of Association the terms shares and/or shareholders are used without any further specification, these terms shall refer to the common shares and the preference shares and holders of such shares respectively.

82035180 M 3748240 / 1

2

4. The company shall not co-operate with the issuance of depositary receipts in respect of its shares.

5. Each outstanding preference share may be converted by the holder thereof into a common share on such terms and conditions as shall be determined by the board of supervisory directors at the time the preference shares are issued. At conversion, the preference share concerned shall acquire all characteristics of a common share. Conversion shall not take place if and insofar as the number of outstanding common shares would exceed the number of common shares referred to in paragraph 1 of this article.

ISSUES OF SHARES

Article 5.

1. Shares that have not yet been issued shall, up to the amount of the authorized capital, with due observance of the provisions of the (Dutch) Civil Code, be capable of being issued by virtue of a resolution of the board of supervisory directors. The authority or the board of supervisory directors, as referred to in the preceding sentence, shall terminate five years after the date of execution of this deed, unless the general meeting has extended such authority.

2. In case the board of supervisory directors no longer has the authority referred to in paragraph 1 of this Article, any resolution to issue shares shall require the prior approval of the board of supervisory directors.

3. Any resolution to issue shares shall stipulate the terms and conditions of issuance.

PRE-EMPTIVE RIGHTS.

Article 6.

1. Except as provided below, in the event of the issue of new common shares, each holder of common shares shall have a pre-emptive right to subscribe to such shares pro rata to his existing holding of such shares. No pre-emptive rights are attached to shares issued to employees of the company or employees of a group company. Shareholders shall furthermore have no pre-emptive right in respect of shares issued for a non-cash contribution.

The holders of preference shares shall have no pre-emptive rights to subscribe to shares, whereas holders of common shares shall have no pre-emptive rights to subscribe to preference shares.

2. Pre-emptive rights can, with due observance of the relevant provisions of the (Dutch) Civil Code, be restricted or excluded by virtue of a resolution of the board of supervisory directors. The provisions in article 5, paragraph 1, second sentence, and article 5, paragraph 2 shall mutatis mutandis apply.

3. The company shall announce the issue of shares to which pre-emptive rights are attached and the period in which that right is capable of being exercised in a written notification to all the shareholders sent to the addresses set forth in the register of shareholders within fourteen days of such a resolution being passed. Pre-emption rights with respect to an issue shall be capable of being exercised only during the four weeks after the day the announcement relating to such issue has been sent out.

4. The provisions in article 5 and in this article shall apply as well to the granting of rights to subscribe for shares (other than rights granted to employees of the company or employees of a group company) within the meaning of Article 2:96A of the (Dutch) Civil Code.

82035180 M 3748240 / 1

3

Shareholders, however, shall have no pre-emptive rights for shares which are being issued to a person who exercises a previously acquired right to subscribe for shares.

PAYMENT FOR SHARES

Article 7.

1. The full nominal amount of the shares must be paid in on issue. It may be stipulated though that a part of the nominal amount of the preference shares, not exceeding three quarters thereof, needs only be paid after the company has called it in. If a share is subscribed for at a higher price, the balance of these amounts must be paid in on issue.

2. Payment for a share must be made in cash insofar as no other manner of payment has been agreed on. Payment in foreign currency can be made only with the approval of the company, which approval shall be deemed given upon acceptance of foreign currency by the company.

3. Neither the company, nor any of its subsidiaries shall be allowed to grant security, provide a quotation guarantee, to guarantee in any other way or to bind itself jointly or severally with or for others with a view to the subscription or acquisition of shares or depositary receipts for shares in the company by others.

The company and its subsidiaries may only provide loans, with a view to the subscription for or acquisition by others of shares in the capital of the company or depositary receipts therefor, with due observance of the provisions of Article 2:98c (2-7) of the (Dutch) Civil Code.

ACQUISITION AND TRANSFER BY THE COMPANY OF SHARES IN ITS OWN SHARE CAPITAL

Article 8.

1. Upon any issue of shares the company cannot subscribe for its shares.

2. The company may acquire fully-paid shares in its own capital but only with due observance of the provisions in Article 2:98 of the (Dutch) Civil Code and furthermore with the authorization of the board of management for such acquisition by the general meeting. Such authorization shall be valid for not more than eighteen months. The general meeting must specify in the authorization the number of shares which may be acquired, the manner in which they may be acquired and the limits within which the price must be set.

3. No authorization, as referred to in paragraph 2, shall be required for any acquisition by the company of its own shares for the purpose of transferring the same to employees of the company or of a group company under a scheme applicable to such employees. The provision in article 2:98, paragraph 5 of the (Dutch) Civil Code shall be applicable to any such acquisition.

4. Alienation of shares held by the company in its own capital shall be effected only in pursuance of a resolution of the board of supervisory directors. Upon taking the resolution to alienate such shares, the terms and conditions of such alienation shall also be determined by the board of supervisory directors.

REDUCTION OF THE ISSUED SHARE CAPITAL

Article 9

1. The general meeting shall, upon a proposal thereto by the board of supervisory directors, have power to pass a resolution to reduce the issued share capital either by cancelling shares or by reducing the par value of the shares by means of an amendment to the company's Articles of Association but only with due

82035180 M 3748240 / 1

4

observance of the provisions in article 2:99 of the (Dutch) Civil Code.

2. A resolution to cancel shares may only relate (i) to shares which the company holds in its own share capital or of which it holds the depositary receipts, (ii) to preference shares which may be cancelled on redemption or (iii) to the balloted preference shares that may be balloted for redemption by the board of management.

3. Partial repayment on shares or exemption from the obligation to pay up shall only be allowed in the event of implementing a resolution to reduce the amount of the shares. Such repayment or exemption shall be allowed pro rata on all shares. The pro rata requirement may be abandoned if all shareholders consent.

4. The notice convening a meeting at which a resolution, as mentioned in this article, is to be passed shall state the purpose of the reduction of share capital and the manner of implementation.

SHARE CERTIFICATES, SHAREHOLDERS' REGISTER

Article 10.

1. At the request in writing of a shareholder, share certificates shall be issued in respect of the shares held by such shareholder. The form and the contents of the share certificates shall be determined by the board of supervisory directors.

2. Share certificates for more than one share may be made available. Such plural share certificates may at all times be exchanged for singular certificates and vice versa, free of charge.

3. The share certificates shall be signed by a member of the board of management or a transfer agent duly authorized by it for this purpose, either by an original signature or by a facsimile signature.

4. If share certificates are damaged, lost or missing, the board of management or a transfer agent duly authorized by it for this purpose, may issue duplicates thereof and may establish conditions for such issuance. As a result of the issuance of duplicates, the original documents shall become null and void vis-à-vis the company. The new certificates will bear the same numbers and letters of the documents they replace.

5. The shares shall be consecutively numbered per class from 1 onwards.

6. The board of management or a transfer agent duly authorized by it for this purpose, shall keep a register at the office of the company containing the data referred to in article 2:85 of the (Dutch) Civil Code. The register may, at the discretion of the board of management, in whole or in part, be kept in more than one copy and at more than one place.

7. If a share, a usufruct or a right of pledge over a share forms part of undivided property to which Title 7 of Book 3 of the (Dutch) Civil Code is applicable, then the persons jointly entitled thereto - whose names, moreover, must be recorded in the register - shall only be capable of being represented vis à vis the company by one person to be appointed by them for that purpose in a written statement.

The personal details of the representative thus appointed shall be entered into the register, and all notifications and notices to the persons jointly entitled to that undivided property shall be capable of being sent to the address, recorded in the register, of the person thus appointed.

82035180 M 3748240 / 1

5

TRANSFER OF SHARES AND LIMITED RIGHTS TO SHARES

Article 11.

1. The transfer of shares or the transfer or termination of usufruct on shares, or else the establishment or renunciation of usufruct or a right of pledge on shares takes place with consideration of that defined in article 2:86, or else article 2:86c of the (Dutch) Civil Code.

2. Transfers of shares shall be registered on the records maintained by or on behalf of the company for such purpose upon (i) surrender to the company or its duly authorized transfer agent of a certificate or certificates representing the shares requested to be transferred, the transfer provisions on the certificate or certificates being duly completed or on a separate accompanying transfer in such form as the company or transfer agent approves, together with such evidence of the payment of transfer taxes and compliance with other provisions of law as the company or its transfer agent may require, or (ii) if shares are not represented by certificates, upon compliance with such transfer procedures as may be approved by the company or such transfer agent or prescribed by applicable law.

THE RIGHT OF USUFRUCT AND THE RIGHT OF PLEDGE OVER SHARES

Article 12.

1. Each shareholder is entitled to create a right of usufruct or a right of pledge on or over the shares held by him in whole or in part. The shareholder shall have the voting rights for shares over which a right of usufruct or a right of pledge has been established.

2. In deviation from the provision in the last sentence of the previous paragraph, the usufructuary or pledgee shall have the voting rights if this was agreed upon when the limited right was established and the usufructuary or pledgee is a person to whom the shares can freely be transferred in compliance with the provisions in these Articles of Association.

3. If the usufructuary or pledgee is not such a person, he shall only be entitled to have the voting rights where these rights were granted upon creation of the limited right and this has been approved by the board of supervisory directors, which approval may be subject to conditions which shall be stated in the resolution of the board of supervisory directors whereby such granting is approved.

4. If any other person, who is not at the same time a person to whom these Articles of Association allow the shares to be freely transferred, acquires the rights of a pledgee who is entitled to vote, he shall only be entitled to the right to vote if the transfer of the voting right has been approved by the board of supervisory directors.

5. The approval referred to in paragraphs 3 and 4 hereof must be requested by registered letter addressed to the board of supervisory directors.

As promptly as practicable but at least within thirty days after a request for that approval has been received, a meeting of the board of supervisory directors shall be called, to which the request for that approval shall be submitted. If the board of supervisory directors fails to hold the said meeting, then the person who made the request shall himself have authority to call the meeting of the board of supervisory directors subject to due observance of what has been provided thereon in these Articles of Association.

82035180 M 3748240 / 1

6

6. Shareholders not entitled to vote and usufructuaries and pledgees entitled to vote shall have the rights attached to depositary receipts for shares.

MANAGEMENT

Article 13.

1. The company shall have a board of management, consisting of one or more members under the supervision of a board of supervisory directors.

2. The number of managing directors in office shall be fixed by the board of supervisory directors.

3. Natural as well as legal persons can hold the office of managing director.

4. The general meeting shall appoint the managing directors for an unlimited period of time and shall at all times have power to suspend or dismiss any managing director. A resolution to appoint a managing director can only be passed upon recommendation by the board of supervisory directors. Each managing director can at all times also be suspended by the board of supervisory directors. A shareholders' resolution to suspend or dismiss a managing director must be passed by a two thirds majority of the valid votes cast representing more than half of the issued share capital. The provision in article 2:120, paragraph 3, (Dutch) Civil Code shall not be applicable.

5. The appointment of the managing directors may result from a binding nomination, which provides for at least two persons for each vacancy to be filled, made by the board of supervisory directors within three months of such board being invited by means of a registered letter to do so by the board of management. In case no binding nomination has been made within the abovementioned period, the general meeting shall be free in its choice. The general meeting shall also be free in its choice if it deprives any nomination of its binding character in a resolution passed by at least two thirds of the valid votes cast at a meeting where more than half of the issued share capital is present or represented. The provisions in article 2:120, paragraph 3, (Dutch) Civil Code shall not be applicable.

6. If, in the event of suspension of a managing director, after three months no resolution has been passed by the general meeting to dismiss him, the suspension shall terminate.

7. A managing director shall be given the opportunity to account for his actions in the general meeting where his suspension or discharge is discussed and have an adviser assist him therein.

8. The board of supervisory directors shall decide on the remuneration and the further terms and conditions of employment for each of the managing directors.

DUTIES AND POWERS

Article 14.

1. The board of management shall, subject to the limitations contained in these Articles of Association, be in charge of the management of the company.

2. If the board of management consists of more than one board member, the board of management shall appoint one of them chairman. In that case, it may also appoint a vice-chairman.

3. The board of management shall meet whenever its chairman or two other members of that board considers this necessary. Meetings can be held both in The Netherlands and abroad. Notice of its meetings shall be given by the chairman of the board of management - stating the matters to be dealt with - and in the event of his prevention or permanent, absence by one of the other

82035180 M 3748240 / 1

7

managing directors; the period of notice of the meeting being at least three days. The managing directors shall be entitled to have themselves represented by any other member of the board of management by means of an authorization in writing.

4. The board of management shall have power to pass resolutions outside meetings as well, provided this be done (i) by unanimous vote and further in writing, by telegraph, by telefax or by telex messages or (ii) by telephone by a majority of the members of the board of management then in office and provided that all the managing directors have been consulted on the resolution to be passed and none of them objects against the applicable manner of passing a resolution.

5. The board of management shall pass all resolutions adopted at meetings with an absolute majority of the votes of all the managing directors in office, excluding any suspended managing directors. In the event of an equal division of votes, the chairman of the board of management shall have the deciding vote.

6. The ruling pronounced by the chairman of the board of management concerning the result of a vote, as well as the ruling concerning the contents of a resolution that has been passed, insofar as a vote was taken about a proposal other than in a written form, shall be decisive.

If, however, immediately after a ruling as referred to in the previous sentence is pronounced, its correctness is disputed, a new vote is taken provided that this is required by a majority of votes, or if, in the event of the first vote not being taken by call or not being a written one, one of those present and entitled to vote should wish so. This new vote nullifies the legal consequences of the original vote.

7. The board of management shall need the approval of the general meeting for decisions relating to the closing down - including the transfer (of beneficial use) - of all or substantially all of the business of the company.

8. Furthermore, the board of management shall need the approval of the board of supervisory directors for such management decisions as the latter board shall have decided upon by means of a resolution passed especially for this purpose of which it has informed the board of management.

9. The absence of the approval required in accordance with paragraphs 7 and 8 of this article and paragraph 3 of article 15 shall not affect the powers of representation of the board of management or of the managing directors.

10. The board of management shall have the obligation to act in pursuance of the directions of the board of supervisory directors regarding the general outlines of the financial, social and economic policies and regarding personnel management within the company.

11. In the event of the prevention or permanent absence of one or more managing directors the remaining managing director(s) shall be in charge of the entire management of the company; in the event of the prevention or permanent absence of all the managing directors or of the sole managing director there must at all times be a person, who has been appointed for that purpose by the board of supervisory directors, to be in that event temporarily in charge of the management of the company.

12. The members of the board of management shall have the obligation to attend the general meetings, unless the general meeting should decide otherwise; in the general meetings their role will be an advisory one.

82035180 M 3748240 / 1

8

REPRESENTATION

Article 15.

1. The board of management shall represent the company. The company can also be represented by each managing director acting alone.

The board of management may authorise each employee to represent the company solely within limits to be laid down in such authorization. The board of management shall determine such employee's title.

2. If a managing director has an interest that conflicts with that of the company, the board of management as well as each managing director shall nevertheless be able to represent the company, provided this is done in compliance with the provisions of these Articles of Association.

THE BOARD OF SUPERVISORY DIRECTORS

Article 16.

1. The company shall have a board of supervisory directors consisting of one or more natural persons.

2. The number of supervisory directors in office shall be fixed by the board of supervisory directors.

3. If the board of supervisory directors consists of three, four or five members, then the board of supervisory directors itself may appoint one member of the board of supervisory directors. If the board of supervisory directors consists of six or more members, the board of supervisory directors itself may appoint two members. The board of supervisory directors shall only be entitled to effect any of the appointments as described in the preceding two sentences of this paragraph in case of death, resignation or dismissal of a member of the board of supervisory directors without the general meeting having appointed a successor. Each of the above appointments will lapse as soon as the general meeting has appointed a successing member of the board of supervisory directors in accordance with the following provisions of this paragraph. The board of supervisory directors shall at all times be empowered to suspend or dismiss each member of the board of supervisory directors appointed by it. The general meeting shall appoint all other supervisory directors with due observance of and in the way as provided in article 13, paragraph 5 and shall at all times be empowered to suspend or dismiss any such supervisory director with due observance of the provisions in article 13, paragraph 4. A resolution to appoint a supervisory director can only be passed upon recommendation by the board of supervisory directors.

4. The general meeting of shareholders shall determine the remuneration of the supervisory directors. Any reasonable expenses incurred by supervisory directors in this capacity shall be refunded to them. The notes to the annual accounts shall contain full and detailed information on the amount and structure of the remuneration  of individual supervisory directors. No personal loans can be granted to the member of the management board unless it is in the normal conduct of the company and the supervisory board has given its approval.

5. It shall be the duty of the board of supervisory directors to exercise supervision over the board of management's conduct of affairs and over the general course of business in the company and the business enterprise connected with it. It shall offer advice to the board of management. In discharging their duties the board of supervisory directors shall have regard for the interests of the company and the business enterprise connected with it.

82035180 M 3748240 / 1

9

6. The board of management shall supply all such information regarding the af fairs of the company to any one of the supervisory directors who should require this. The board of supervisory directors shall have power to examine all books, documents and correspondence of the company and to take cognizance of all acts that have taken place; each supervisory director shall have access to all buildings and sites that are being used by the company.

7. The board of supervisory directors shall be entitled to ask the assistants of experts in the exercise of its duties for account of the company. In addition, the board of supervisory directors may appoint advisors to the company, without regard to any age limitation, and may grant to such advisors the title of honorary member of the board of supervisory directors or any other title it may resolve upon. The board of supervisory directors shall appoint a secretary, who needs not be a member of such board, and make arrangements for his substitution in case of his absences at meetings of such board. The secretary shall keep minutes of the proceedings at meetings of the board of supervisory directors. The minutes shall be adopted at the same or in a subsequent meeting and shall be signed by the chairman and the secretary as evidence thereof.

8. If the board of supervisory directors consists of more than one board member, the board of supervisory directors shall appoint one of them chairman. In that case, it may also appoint a vice-chairman. The board of supervisory directors shall furthermore be empowered to appoint one or more of them to be primarily in charge of the day-to-day supervision of the board of management.

Subject to any limitations that may be imposed by applicable law, the board of supervisory directors may delegate any of its powers to committees consisting of such member or members of its body as it thinks fit; any committee as formed shall in the exercise of the power so delegated conform to any regulations that may be imposed on it by the board of supervisory directors. The board of supervisory directors may draw up its own charter, which will regulate the formalities for meetings of the board of supervisory directors to be observed, in addition to the foregoing provisions.

9. The board of supervisory directors shall meet whenever its chairman or two other members of that board considers this necessary. Meetings can be held both in The Netherlands and abroad. Notice of its meetings shall be given by the chairman of the board of supervisory directors - stating the matters to be dealt with - and in the event of his prevention or permanent absence by one of the other supervisory directors; the period of notice of the meeting being at least eight days. The supervisory directors shall be entitled to have themselves represented by any other member of the board of supervisory directors by means of an authorization in writing.

If asked to do so, the board of management shall attend the meetings of the board of supervisory directors; in that event their role shall be an advisory one.

10 The board of supervisory directors shall have power to pass resolutions outside meetings as well, provided this be done (i) by unanimous vote and further in writing, by telegraph, by telefax or by telex messages or (ii) by telephone by a majority of the members of the board of supervisory directors then in office and provided that all the supervisory directors have been consulted on the resolution to be passed and none of them objects against the applicable manner of passing a resolution.

82035180 M 3748240 / 1

10

11. The board of supervisory directors shall pass its resolutions adopted at meetings with an absolute majority of the votes of all the supervisory directors in office, excluding any suspended supervisory directors.

In the event of an equal division of votes, the chairman of the board of supervisory directors shall have the deciding vote.

12. The ruling pronounced by the chairman of the board of supervisory directors regarding the outcome of a vote as well as the ruling concerning the contents of a resolution passed by the board of supervisory directors, provided that a vote has been held about a proposal not recorded in writing, shall be decisive.

If, however, the correctness of a ruling as referred to in the preceding sentence is challenged immediately after the ruling has been pronounced, then a new vote shall be held, whenever a majority of those present and entitled to vote or, if the original vote was not taken by call or ballot papers, whenever any one of those present and entitled to vote should wish so. This new vote shall nullify the legal consequences of the original vote.

13. All resolutions of the board of supervisory directors, including those passed outside meetings, shall be entered into a register of minutes.

14. When the company wants to establish proof of any resolution of the board of supervisory directors, the signature of one member of that board on the document in which the resolution is contained, shall suffice.

15. A supervisory director may be appointed to the supervisory board for a three-year term. With due observance of the first sentence, each supervisory director shall be eligible for immediate re-appointment. The supervisory board shall draw up a retirement rota in order to avoid, as far as possible, a situation in which re-appointments occur simultaneously. The rota shall be made available and shall, in any event, be put on the company's website.

A member of the supervisory board shall be re-appointed only after careful consideration.

16. If for any reason whatsoever one or more supervisory directors are permanently absent, then the remaining supervisory directors shall, as long as at least one supervisory director is in office, constitute a body capable of acting until the vacancy(ies) has/have been filled.

17. If there is only one supervisory director, he shall have all the powers and obligations that these Articles of Association confer and impose on the board of supervisory directors and its chairman.

18. The members of the board of supervisory directors shall have the obligation to attend the general meetings of shareholders; in these meetings their role will be an advisory one.

INDEMNIFICATION

Article 17.

1. Each person who was or is made a party or is threatened to be made a party to or is involved in any action, suit or proceeding, whether civil, criminal, administrative or investigative (hereinafter a “proceeding”), by reason of the fact that he or she, is or was or has agreed to become a supervisory or managing director of the company or is or was serving or has agreed to serve at the request of the company as a supervisory or managing director of another company or of a partnership, joint venture, trust or other enterprise, including service with respect to employee benefit plans, whether the basis of such proceeding is alleged action in an official capacity as a supervisory or

82035180 M 3748240 / 1

11

managing director of the company or in any other capacity while serving or having agreed to serve as a supervisory or managing director, shall be indemnified by the company  against all expense, liability and loss (including without limitation, attorneys’ fees, judgments, fines, excise taxes or penalties and amounts paid or to be paid in settlement) reasonably and actually incurred or suffered by such person in connection therewith.

2. Such indemnification shall continue as to a person who has ceased to serve in the capacity which initially entitled such person to indemnity hereunder and shall inure to the benefit of his or her heirs, executors of his or her last will and testament, and the administrators of his estate.

3. If the damage was caused by seriously culpable conduct (which the parties intend to be functionally the same as “gross negligence or wilful misconduct” standards used in New York state law which, while not superseding the Dutch law governing the relationship between Dutch companies and the directors thereof, reflects the parties’ intent as to the principles which, in the absence of clear Dutch law to the contrary, should be used for purposes of this indemnity) on the part of the relevant supervisory director or managing director, no right to indemnification shall exist.

4. The right to indemnification shall include the right to be paid by the company the expenses incurred in defending any such proceeding in advance of its final disposition. The payment of such expenses incurred by a current, former or proposed supervisory or managing director in his or her capacity as a supervisory or managing director or proposed supervisory or managing director in advance of the final disposition of a proceeding, shall be made only upon delivery to the company of a written undertaking, by or on behalf of such person seeking indemnification, to repay all amounts so advanced if it shall ultimately be determined that such person seeking indemnification is not entitled to be indemnified under this Article 17 or otherwise.

5. The managing or supervisory director shall not accept any liability towards third parties and not enter into a settlement agreement without the prior written consent of the company. The company and the managing or supervisory director shall use all reasonable efforts, but at the company’s sole expense, to cooperate in order to agree on the defense against any action against the managing or supervisory director unless such defense is not, in the opinion of counsel to the person seeking indemnification, likely to be successful.

6. If a written claim received by the company from or on behalf of an indemnified party under this Article 17 is not paid in full by the company within ninety days after such receipt, the claimant may at any time thereafter bring suit against the company to recover the unpaid amount of the claim and, if successful in whole or in part, the claimant shall be entitled to be paid also the expense of prosecuting such claim.

7. The right to indemnification and the advancement and payment of expenses conferred in this Article 17 shall not be exclusive of any other right which any person may have or hereafter acquire under any law (common or statutory), provision of the Articles of Association of the company, bylaw, agreement, vote of stockholders or disinterested supervisory or managing directors or otherwise.

8. The company may maintain insurance, at its expense, to protect itself and any person who is or was serving as a supervisory or managing director of the company or is or was serving at the request of the company as a supervisory or

82035180 M 3748240 / 1

12

managing director of another company, partnership, joint venture, trust or other enterprise, including service with respect to employee benefit plans against any expense, liability or loss, whether or not the company would have the power to indemnify such person against such expense, liability or loss under Dutch law.

9. If this Article 17 or any portion hereof shall be invalidated on any ground by any court of competent jurisdiction, then the company shall nevertheless indemnify each supervisory or managing director of the company and any person who is or was serving at the request of the company as a supervisory or managing director of another company, partnership, joint venture, trust or other enterprise, including service with respect to employee benefit plans, as to costs, charges and expenses (including without limitation, attorneys’ fees, judgments, penalties or fines, and amounts paid or to be paid in settlement) with respect to any action, suit or proceeding, whether civil, criminal, administrative or investigative to the full extent permitted by any applicable portion of this Article 17 that shall not have been invalidated and to the fullest extent permitted by applicable law.

10. For purposes of this Article 17, reference to the “company” shall include, in addition to the company, any constituent company (including any constituent of a constituent) absorbed in a consolidation or merger prior to (or, in the case of an entity specifically designated in a resolution of the board of supervisory  directors, after) the adoption hereof and which, if its separate existence had continued, would have had the power and authority to indemnify its supervisory or managing directors of such constituent company and so that any person who is or was a supervisory or managing director of such constituent company, or is or was serving at the request of such constituent company as a supervisory or managing director of another company, partnership, joint venture, trust or other enterprise, including service with respect to employee benefit plans, shall stand in the same position under the p rovisions of this Article 17 with respect to the resulting or surviving company as he or she would have with respect to such constituent company if its separate existence had continued.

11. An amendment to this article shall not impair the rights of a person who was a supervisory director or managing director after the introduction of this article but before the amendment. The obligations of the company towards such persons shall remain in effect as if the article had not been amended.

GENERAL MEETINGS

Article 18.

1. Not less than one general meeting shall be held each year within six months of the close of the financial year; the purpose of the meeting shall, among other things, be:

a. to discuss the annual accounts and, if required by law, the annual report and the other information referred to in Article 2:392 (Dutch) Civil Code, unless an extension of time has been granted for the preparation of the annual accounts;

b. to discuss whether or not to adopt the annual accounts, unless an extension of time has been granted for the preparation thereof;

c. to determine the profit appropriation;

d.           to decide whether or not to discharge the board of management;

e. to do all other things required by law.

82035180 M 3748240 / 1

13

2. Within three months after the board of management first had good reason to believe that the shareholders' equity of the company has decreased to an amount equal to or less than one half of the paid-up and called parts of the share capital, a general meeting shall be acting held for the purpose of discussing any measures that may have to be taken.

Furthermore, general meetings shall be held as often as the majority of the managing directors then in office or the majority of the members of the board of super­visory directors then in office considers it necessary, without prejudice to the provisions in the next para­graph hereof.

3. General meetings can furthermore be convened by the shareholders with due observance of the provisions in article 2:110 of the (Dutch) Civil Code.

4. General meetings shall be held in the place where the company has its corporate seat as contained in these Articles of Association, as well as in Delft, Rotterdam, The Hague, Utrecht or Haarlemmermeer. At a general meeting, held at a different place, valid resolutions shall also be capable of being passed if the entire issued share capital is represented.

5. Notice of the meetings must be given to the persons entitled to attend meetings, without prejudice to the provisions of paragraph 3 of this article, by or on behalf of the board of management or the board of super­visory directors. The notice convening a general meeting shall be published by advertisement which shall at least be published in a nationally distributed daily newspaper in The Netherlands. In addition, the shareholders shall be notified by means of letters delivered through the mails; the period of notice shall be at least fifteen days, not including the day of the notice and the day of the meeting.

Notice of a meeting may also be given by sending an electronic message that is readable and capable of being produced in writing to the address notified for this purpose to the company by those persons entitled to attend meetings that have consented to receiving notice in this manner.

6. The notice of the meeting shall contain the agenda of the meeting.

7. If a proposal to amend the company's Articles of Association is to be dealt with, a copy of that proposal, in which the proposed amendments are stated verbatim, shall be made available for inspection to the persons who are entitled to attend meetings inter alia at the office of the company where it maintains its corporate seat, as from the day of the notice of the meeting until after the close of that meeting, and each of them shall be entitled, upon his request, to obtain a copy thereof, without charge unless such a copy is attached to the notice of the meeting.

8. If the provisions laid down by law or by these Articles of Association in relation to giving notice of meetings, drawing up the agendas for such meetings and making available for inspection those matters which are to be dealt with have not been complied with, then valid resolutions shall nevertheless be capable of being passed, provided that the entire issued share capital be represented at the meeting in question and provided that the resolution be passed unanimously.

Article 19.

1. The chairman of the board of supervisory directors shall chair the meeting. If such chairman is not present at any such meeting, the general meeting shall itself decide who is to chair the meeting. The chairman of the meeting may adopt rules and regulations relating to the conduct of such meeting.

82035180 M 3748240 / 1

14

2. The chairman shall appoint one of those present to act as secretary whose duty it shall be to draw up the minutes of the meeting and the chairman shall, together with the secretary, confirm and adopt the minutes, in proof of which they shall sign these. The minutes shall be entered into a register of minutes. If an official notarial record is made of the matters dealt with at a meeting then minutes need not be drawn up.

3. Each of the persons entitled to attend meetings shall have the right to be represented at a meeting by a proxy duly authorized in writing.

4. The board of management may decide that each person entitled to attend meetings is entitled, in person or by written proxy, through an electronic means of communication, to participate in the general meeting, to take the floor and, to the extent applicable, to exercise voting rights. In order to participate in the general meeting pursuant to the preceding sentence it is necessary that the person entitled to attend meetings can, via the selected electronic means of communication, be identified, directly take cognisance of the matters handled in the meeting and, to the extent applicable, exercise the voting rights.

5. The board of management may attach conditions to the use of the electronic means of communication. These conditions shall be made known in the notice of the meeting.

6. The board of management may decide that votes cast electronically prior to the general meeting shall be equivalent to votes cast during the meeting. These votes shall be cast no earlier than on the thirtieth day before the day of the meeting. For the purpose of applying this paragraph, persons with voting rights shall be those that have such rights on a date to be set in the notice of a general meeting and are registered as such in a register designated by the board of management, irrespective of who have voting rights on the shares at the time of the general meeting. The final registration date may not be set earlier than the thirtieth day before that of the meeting.

Article 20.

1. Each common share and each preference share entitles the holder thereof to cast one (1) vote.

2. At general meetings the company shall not be capable of casting votes for shares in its own share capital which are held by itself or by one of its subsidiaries; nor shall it be capable of doing so for shares in its own share capital of which the company or one of its subsidiaries holds the depositary receipts for shares. Usufructuaries and pledgees of shares held by the company and its subsidiaries are not excluded from the right to vote, provided the right of usufruct or the right of pledge was established over shares before they were held by the company or one of its subsidiaries. The company or one of its subsidia­ries shall not be capable of casting votes for shares over which it has a right of usufruct or a right of pledge.

3. When determining whether a particular proportion of the share capital is represented, or alternatively, whether a majority represents a particular proportion of the share capital, the amount of shares to which no voting rights are attached shall be subtracted from the share capital.

4. Votes on matters of business shall be held verbally, those concerning persons by means of unsigned closed ballot papers, unless in either case the chairman of the meeting should, without objection from any of those present and entitled to vote, decide on or allow any other manner of voting. If the vote concerns an

82035180 M 3748240 / 1

15

election of persons, a person entitled to attend meetings present at the relative meeting can also demand a vote by a secret ballot.

5. All resolutions of the general meeting shall be passed with a two-thirds majority of the valid votes cast representing more than half of the issued share capital, except - without prejudice to the provisions in article 13, paragraphs 4 and 5 and article 16, paragraph 3:

(i) for the resolutions to be passed upon recommendation by the board of supervisory directors, which resolutions (except as required in (ii) below) may be passed with an absolute majority of the votes cast, without regard to the number of shares represented at the meeting;

ii) for the resolutions to amend the Articles of Association, which resolutions can only be passed with a two-thirds majority of the valid votes cast representing more than half of the issued share capital and further only on the proposal of the board of management, which proposal must be approved by the board of supervisory directors.

6. Blank votes and abstentions shall not be counted as votes cast.

7. If there is an equal division of votes on a proposal about business matters, no decision shall be taken.

8. In the event a vote is taken to elect one of two candidates and there is an equal division of votes, it shall be decided by drawing lots which of these has been elected, under the restriction, however, that if persons from a binding nomination list are to be elected, then the higher ranking nominee is elected.

9. The ruling concerning voting results pronounced by the chairman during the meeting shall be decisive. The same shall also apply to the contents of a resolution passed by the meeting, provided that a vote has been held about a proposal not recorded in writing.

10. If the correctness of a ruling as referred to in the preceding paragraph is challenged, however, immediately after the ruling has been pronounced, then a new vote shall be held whenever a majority of the general meeting should wish so, or, if the original vote was not taken by call or by ballot papers, whenever any one of the person: entitled to vote should wish so.

This new vote shall nullify the legal consequences of the original vote.

11. The board of management shall keep a record of the resolutions that have been passed. This record shall be open to inspection by the persons entitled to attend meetings at the registered office of the company. Upon request, each of them shall receive a copy of or an ex­tract from this record against payment of cost at most.

Article 21.

1. Except if the company has usufructuaries and pledgees entitled to vote, resolutions of shareholders shall alternatively be capable of being passed in writing - which shall include telegraphic, telefax and telex messages - instead of at a general meeting, provided that these are passed with a unanimous vote of all persons who are entitled to vote.

2. The board of management shall enter the resolutions that have been passed in the manner specified in the preceding paragraph of this article, in the register of minutes of the general meetings and shall mention this at the next general meeting.

82035180 M 3748240 / 1

16

MEETINGS OF HOLDERS OF SHARES OF A SPECIAL CLASS

Article 22.

1. Meetings of holders of shares of a special class shall be held in all instances, which by virtue of these Articles of Association require a resolution of the meeting of holders of shares of a special class and, furthermore, whenever the board of management and/or the board of supervisory directors considers it necessary or whenever one or more persons holding the voting rights over shares of a special class submit(s) a written request to this effect to the board of management and/or the board of supervisory directors, stating exactly what issues are to be dealt with.

2. Article 18 paragraphs 4 to 8 inclusive, Article 19 paragraphs 2 and 3 and Article 20 paragraphs 1 to 11 inclusive shall mutatis mutandis be applicable to meetings of holders of shares of a special class.

3. If, after a request as mentioned at the end of paragraph 1, the board of management and/or the board of supervisory directors fails to convene a meeting of holders of shares of a special class, in the sense that it be held within four weeks of receipt of that request, the requestors shall themselves be empowered to convene a meeting.

4. A meeting of holders of shares of a special class shall itself decide who is to chair its meetings.

5. The chairman of a meeting of holders of shares of a special class shall decide upon allowing other persons to attend the meeting, apart from those holding the voting rights over the relative shares.

6. Resolutions of a meeting of holders of shares of a special class shall alternatively be capable of being passed in writing - which shall include telegraphic, telefax and telex messages - provided these are passed unanimously by all the persons entitled to vote.

EXAMINATION BY EXPERT

Article 23.

1. The general meeting shall have authority - and if this is required by provision of law it shall have the obligation - to instruct an expert as referred to in Article 2:393 of the (Dutch) Civil Code, whose duty it shall be to examine the annual accounts drawn up by the board of management, to lay a report of their findings before the board of management and to make a statement with regard thereto.

2. If the general meeting fails to instruct the expert as referred to in paragraph 1 of this article, this instruction shall be made by the board of management.

3. The instruction shall be capable of being cancelled at all times by the general meeting and by the person who instructed the expert.

FINANCIAL YEAR, ANNUAL ACCOUNTS

Article 24.

1. The financial year of the company shall coincide with the calendar year.

2. The board of management shall close the books of the company as at the last day of every financial year and shall within five months thereafter - except if extension of that period to a maximum of six months has been granted by resolution of the general meeting because of special circumstances - draw up annual accounts consisting of a balance sheet, a profit and loss account and explanatory notes and within this period it shall make these documents available for inspection by the shareholders at the office of the company. These documents will also be submitted to the board of supervisory directors. Within

82035180 M 3748240 / 1

17

this period the board of management shall submit the annual report to the general meeting as well. The annual accounts shall be signed by all the managing directors and members of the board of supervisory directors; if any signature is missing, the reason therefore shall be stated in the annual accounts.

3. The company shall ensure that the annual accounts that have been drawn up, the annual report and the particulars that have to be added by virtue of paragraph 1 of Article 2:392 of the (Dutch) Civil Code are available at its office as from the day of the notice of the general meeting at which they are to be dealt with.

The persons entitled to attend meetings shall have the right to review these documents at the company's office and to obtain copies thereof free of charge.

4. What has been provided in paragraphs 2 and 3 of this article in relation to the annual report and the particulars to be added by virtue of paragraph 1 of Article 2:392 of the (Dutch) Civil Code shall not be applicable if Article 2:396, paragraph 6, first sentence or Article 2:403 of the (Dutch) Civil Code is applicable to the company.

5. The general meeting shall adopt the annual accounts. Adoption of the annual accounts shall not serve to discharge a managing director or a supervisory director.

6. The company shall proceed to publish the documents and data mentioned in this article, if and to the extent and in the manner that this is stipulated in Articles 2:394 and following of the (Dutch) Civil Code.

DISTRIBUTIONS

Article 25.

1. From the profits appearing from the annual accounts as adopted, such an amount shall be reserved by the company as shall be determined by the board of supervisory directors.

The profits remaining thereafter shall be treated in accordance with the provisions of the following paragraphs of this article.

2. From the profits remaining, after application of the provisions in paragraph 1 above, and available for distribution, first a non-cumulative cash dividend calculated on the basis of the aggregate of the par value of the preference shares and any share premium paid thereon, shall be made on the preference shares, less any interim distributions made in accordance with paragraph 5 hereunder. The percentage of such dividend shall be determined by the board of supervisory directors at the time of the first issuance of the relative preference shares. This rate of dividend can be adjusted by unanimous resolution of all persons entitled to vote. Any distribution on the preference shares shall not take place if all holders of the preference shares, unanimously so decide.

3. The profits remaining after the distribution referred to in paragraph 2 above are at the disposal of the general meeting for distribution on the common shares equally and proportionally and/or for reservation.

4. The company can make distributions to its share­holders and other persons entitled to its profits that are capable of being distributed, but only to the ex­tent that its shareholders' equity exceeds the paid-up and called parts of its share capital increased by the reserves that it must maintain by law or under the present Articles of Association.

5. With due observance of the provisions in paragraph 4 of article 2:105 of the (Dutch) Civil Code and in paragraph 4 of this article, the supervisory board may resolve that an interim dividend shall be paid. The supervisory board may

82035180 M 3748240 / 1

18

resolve to pay interim dividend completely or partly other than in cash.

6. The general meeting may resolve that (interim) dividends shall wholly or partly be paid otherwise than in cash.

7. Unless the general meeting decides on a specific date dividends shall be made payable promptly after they have been declared

8. Dividends that have not been collected within five years after they have become payable, shall be forfeited to the company.

LIQUIDATION AND WINDING UP

Article 26.

1. In the event of the company being liquidated it shall be wound up by the board of management unless the general meeting decides otherwise.

2. The general meeting shall decide on the remuneration of the liquidators and of those who have been charged with the supervision of the winding up.

3. During the winding up, these Articles of Association shall, in as far as possible, remain of full force and effect.

4. Out of the balance of the company's equity, after the expenses of liquidation and the company's debts have been paid, to the holders of preference shares shall be distributed first the amounts paid up on such preference shares. The balance remaining after application of the immediately preceding sentence shall be distributed to the holders of common shares pro rata to the amount of common shares each of such shareholders holds. No distribution upon liquidation shall be made to the company itself for shares which the company holds in its own share capital.

5. After completion of the winding up the books and documents of the liquidated company shall for ten years remain in the custody of a person who shall be capable of being appointed for that purpose by the general meeting in their resolution to liquidate the company. If an appointment as aforesaid has not been made by the general meeting, then the appointment shall be made by the liquidators.

82035180 M 3748240 / 1

19

EX-31.1

Certification

 Exhibit 31.1

I, David M. Demshur, certify that:

1. I have reviewed this quarterly report on Form 10-Q of Core Laboratories N.V. (the "Registrant");

2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the Registrant as of, and for, the periods presented in this report;

4. The Registrant's other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the Registrant and have:

(a) Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the Registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

(b) Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

(c) Evaluated the effectiveness of the Registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

(d) Disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the Registrant's most recent fiscal quarter (the Registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the Registrant's internal control over financial reporting; and

5. The Registrant's other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the Registrant's auditors and the audit committee of the Registrant's board of directors (or persons performing the equivalent functions):

(a) All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the Registrant's ability to record, process, summarize and report financial information; and

(b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the Registrant's internal control over financial reporting.

Date: July 23, 2010	By:	/s/ David M. Demshur
		David M. Demshur
		Chief Executive Officer

EX-31.2

Certification

Exhibit 31.2

I, Richard L. Bergmark, certify that:

1. I have reviewed this quarterly report on Form 10-Q of Core Laboratories N.V. (the "Registrant");

2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the Registrant as of, and for, the periods presented in this report;

4. The Registrant's other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the Registrant and have:

(a) Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the Registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

(b) Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

(c) Evaluated the effectiveness of the Registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

(d) Disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the Registrant's most recent fiscal quarter (the Registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the Registrant's internal control over financial reporting; and

5. The Registrant's other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the Registrant's auditors and the audit committee of the Registrant's board of directors (or persons performing the equivalent functions):

(a) All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the Registrant's ability to record, process, summarize and report financial information; and

(b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the Registrant's internal control over financial reporting.

Date: July 23, 2010	By:	/s/ Richard L. Bergmark
		Richard L. Bergmark
		Chief Financial Officer

EX-32.1

Exhibit 32.1

Certification of

Chief Executive Officer

Pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002

I, David M. Demshur, Chief Executive Officer of Core Laboratories N.V. (the "Company"), hereby certify that the accompanying report on Form 10-Q for the quarter ended June 30, 2010, filed by the Company with the Securities and Exchange Commission on the date hereof fully complies with the requirements of Section 13(a) or 15(d), as applicable, of the Securities Exchange Act of 1934, as amended, (the "Report").

I further certify that the information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

Date: July 23, 2010	/s/ David M. Demshur
	Name: David M. Demshur
	Title: Chief Executive Officer

EX-32.2

Exhibit 32.2

Certification of

Chief Financial Officer

Pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002

I, Richard L. Bergmark, Chief Financial Officer of Core Laboratories N.V. (the "Company"), hereby certify that the accompanying report on Form 10-Q for the quarter ended June 30, 2010, filed by the Company with the Securities and Exchange Commission on the date hereof fully complies with the requirements of Section 13(a) or 15(d), as applicable, of the Securities Exchange Act of 1934, as amended, (the "Report").

I further certify that the information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

Date: July 23, 2010	/s/ Richard L. Bergmark
	Name: Richard L. Bergmark
	Title: Chief Financial Officer